<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN"
"http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" lang="en" xml:lang="en">
<head>
<meta http-equiv="Content-Type" content="text/html;charset=utf-8" />
<meta name="viewport" content="width=device-width, initial-scale=1" />
<title>Genetics</title>
<meta name="author" content="Thanos Apollo" />
<meta name="description" content="Personal notes of microbiology, according to the syllabus of MU-Sofia 2022" />
<meta name="generator" content="Org Mode" />
<style>
  #content { max-width: 60em; margin: auto; }
  .title  { text-align: center;
             margin-bottom: .2em; }
  .subtitle { text-align: center;
              font-size: medium;
              font-weight: bold;
              margin-top:0; }
  .todo   { font-family: monospace; color: red; }
  .done   { font-family: monospace; color: green; }
  .priority { font-family: monospace; color: orange; }
  .tag    { background-color: #eee; font-family: monospace;
            padding: 2px; font-size: 80%; font-weight: normal; }
  .timestamp { color: #bebebe; }
  .timestamp-kwd { color: #5f9ea0; }
  .org-right  { margin-left: auto; margin-right: 0px;  text-align: right; }
  .org-left   { margin-left: 0px;  margin-right: auto; text-align: left; }
  .org-center { margin-left: auto; margin-right: auto; text-align: center; }
  .underline { text-decoration: underline; }
  #postamble p, #preamble p { font-size: 90%; margin: .2em; }
  p.verse { margin-left: 3%; }
  pre {
    border: 1px solid #e6e6e6;
    border-radius: 3px;
    background-color: #f2f2f2;
    padding: 8pt;
    font-family: monospace;
    overflow: auto;
    margin: 1.2em;
  }
  pre.src {
    position: relative;
    overflow: auto;
  }
  pre.src:before {
    display: none;
    position: absolute;
    top: -8px;
    right: 12px;
    padding: 3px;
    color: #555;
    background-color: #f2f2f299;
  }
  pre.src:hover:before { display: inline; margin-top: 14px;}
  /* Languages per Org manual */
  pre.src-asymptote:before { content: 'Asymptote'; }
  pre.src-awk:before { content: 'Awk'; }
  pre.src-authinfo::before { content: 'Authinfo'; }
  pre.src-C:before { content: 'C'; }
  /* pre.src-C++ doesn't work in CSS */
  pre.src-clojure:before { content: 'Clojure'; }
  pre.src-css:before { content: 'CSS'; }
  pre.src-D:before { content: 'D'; }
  pre.src-ditaa:before { content: 'ditaa'; }
  pre.src-dot:before { content: 'Graphviz'; }
  pre.src-calc:before { content: 'Emacs Calc'; }
  pre.src-emacs-lisp:before { content: 'Emacs Lisp'; }
  pre.src-fortran:before { content: 'Fortran'; }
  pre.src-gnuplot:before { content: 'gnuplot'; }
  pre.src-haskell:before { content: 'Haskell'; }
  pre.src-hledger:before { content: 'hledger'; }
  pre.src-java:before { content: 'Java'; }
  pre.src-js:before { content: 'Javascript'; }
  pre.src-latex:before { content: 'LaTeX'; }
  pre.src-ledger:before { content: 'Ledger'; }
  pre.src-lisp:before { content: 'Lisp'; }
  pre.src-lilypond:before { content: 'Lilypond'; }
  pre.src-lua:before { content: 'Lua'; }
  pre.src-matlab:before { content: 'MATLAB'; }
  pre.src-mscgen:before { content: 'Mscgen'; }
  pre.src-ocaml:before { content: 'Objective Caml'; }
  pre.src-octave:before { content: 'Octave'; }
  pre.src-org:before { content: 'Org mode'; }
  pre.src-oz:before { content: 'OZ'; }
  pre.src-plantuml:before { content: 'Plantuml'; }
  pre.src-processing:before { content: 'Processing.js'; }
  pre.src-python:before { content: 'Python'; }
  pre.src-R:before { content: 'R'; }
  pre.src-ruby:before { content: 'Ruby'; }
  pre.src-sass:before { content: 'Sass'; }
  pre.src-scheme:before { content: 'Scheme'; }
  pre.src-screen:before { content: 'Gnu Screen'; }
  pre.src-sed:before { content: 'Sed'; }
  pre.src-sh:before { content: 'shell'; }
  pre.src-sql:before { content: 'SQL'; }
  pre.src-sqlite:before { content: 'SQLite'; }
  /* additional languages in org.el's org-babel-load-languages alist */
  pre.src-forth:before { content: 'Forth'; }
  pre.src-io:before { content: 'IO'; }
  pre.src-J:before { content: 'J'; }
  pre.src-makefile:before { content: 'Makefile'; }
  pre.src-maxima:before { content: 'Maxima'; }
  pre.src-perl:before { content: 'Perl'; }
  pre.src-picolisp:before { content: 'Pico Lisp'; }
  pre.src-scala:before { content: 'Scala'; }
  pre.src-shell:before { content: 'Shell Script'; }
  pre.src-ebnf2ps:before { content: 'ebfn2ps'; }
  /* additional language identifiers per "defun org-babel-execute"
       in ob-*.el */
  pre.src-cpp:before  { content: 'C++'; }
  pre.src-abc:before  { content: 'ABC'; }
  pre.src-coq:before  { content: 'Coq'; }
  pre.src-groovy:before  { content: 'Groovy'; }
  /* additional language identifiers from org-babel-shell-names in
     ob-shell.el: ob-shell is the only babel language using a lambda to put
     the execution function name together. */
  pre.src-bash:before  { content: 'bash'; }
  pre.src-csh:before  { content: 'csh'; }
  pre.src-ash:before  { content: 'ash'; }
  pre.src-dash:before  { content: 'dash'; }
  pre.src-ksh:before  { content: 'ksh'; }
  pre.src-mksh:before  { content: 'mksh'; }
  pre.src-posh:before  { content: 'posh'; }
  /* Additional Emacs modes also supported by the LaTeX listings package */
  pre.src-ada:before { content: 'Ada'; }
  pre.src-asm:before { content: 'Assembler'; }
  pre.src-caml:before { content: 'Caml'; }
  pre.src-delphi:before { content: 'Delphi'; }
  pre.src-html:before { content: 'HTML'; }
  pre.src-idl:before { content: 'IDL'; }
  pre.src-mercury:before { content: 'Mercury'; }
  pre.src-metapost:before { content: 'MetaPost'; }
  pre.src-modula-2:before { content: 'Modula-2'; }
  pre.src-pascal:before { content: 'Pascal'; }
  pre.src-ps:before { content: 'PostScript'; }
  pre.src-prolog:before { content: 'Prolog'; }
  pre.src-simula:before { content: 'Simula'; }
  pre.src-tcl:before { content: 'tcl'; }
  pre.src-tex:before { content: 'TeX'; }
  pre.src-plain-tex:before { content: 'Plain TeX'; }
  pre.src-verilog:before { content: 'Verilog'; }
  pre.src-vhdl:before { content: 'VHDL'; }
  pre.src-xml:before { content: 'XML'; }
  pre.src-nxml:before { content: 'XML'; }
  /* add a generic configuration mode; LaTeX export needs an additional
     (add-to-list 'org-latex-listings-langs '(conf " ")) in .emacs */
  pre.src-conf:before { content: 'Configuration File'; }

  table { border-collapse:collapse; }
  caption.t-above { caption-side: top; }
  caption.t-bottom { caption-side: bottom; }
  td, th { vertical-align:top;  }
  th.org-right  { text-align: center;  }
  th.org-left   { text-align: center;   }
  th.org-center { text-align: center; }
  td.org-right  { text-align: right;  }
  td.org-left   { text-align: left;   }
  td.org-center { text-align: center; }
  dt { font-weight: bold; }
  .footpara { display: inline; }
  .footdef  { margin-bottom: 1em; }
  .figure { padding: 1em; }
  .figure p { text-align: center; }
  .equation-container {
    display: table;
    text-align: center;
    width: 100%;
  }
  .equation {
    vertical-align: middle;
  }
  .equation-label {
    display: table-cell;
    text-align: right;
    vertical-align: middle;
  }
  .inlinetask {
    padding: 10px;
    border: 2px solid gray;
    margin: 10px;
    background: #ffffcc;
  }
  #org-div-home-and-up
   { text-align: right; font-size: 70%; white-space: nowrap; }
  textarea { overflow-x: auto; }
  .linenr { font-size: smaller }
  .code-highlighted { background-color: #ffff00; }
  .org-info-js_info-navigation { border-style: none; }
  #org-info-js_console-label
    { font-size: 10px; font-weight: bold; white-space: nowrap; }
  .org-info-js_search-highlight
    { background-color: #ffff00; color: #000000; font-weight: bold; }
  .org-svg { }
</style>
</head>
<body>
<div id="content" class="content">
<h1 class="title">Genetics</h1>
<div id="table-of-contents" role="doc-toc">
<h2>Table of Contents</h2>
<div id="text-table-of-contents" role="doc-toc">
<ul>
<li><a href="#orgb64afda">Home Page</a></li>
<li><a href="#orgfa071a2">Recommended resources</a></li>
<li><a href="#org3fad9f1">1. Building a pedigree</a></li>
<li><a href="#orgbc868c9">2. Genetic anamnesis</a></li>
<li><a href="#org20e6b73">3. Determining type of inheritance and risk calculation in AR, AD, XD, XR, mitochondrial inheritance</a></li>
<li><a href="#org882e90a">4. Diagnosis, treatment and prevention of beta-thalassemia major. Heterozygous carrier screening - beta-thalassemia minor</a>
<ul>
<li><a href="#orgfe4ef8a">Beta thalessemia major vs minor</a></li>
<li><a href="#orgb947afe">Heterozygous carrier screening</a></li>
<li><a href="#orgd58e582">Diagnosis</a></li>
<li><a href="#orgcf6ab35">Treatment</a></li>
<li><a href="#org7d10523">Prevention</a></li>
</ul>
</li>
<li><a href="#org77b0176">5. Diagnosis,treatment and prevention of cystic fibrosis</a>
<ul>
<li><a href="#orgc067413">Diagnosis</a></li>
<li><a href="#org54f06a5">Treatment</a></li>
<li><a href="#orgefc461d">Prevention</a></li>
</ul>
</li>
<li><a href="#orge9d5616">6. Diagnosis, treatment and prevention of PKU</a>
<ul>
<li><a href="#org4b9dbd2">Diagnosis</a></li>
<li><a href="#org3a3109c">Characteristics</a></li>
<li><a href="#orgcb019bb">Treatment</a></li>
<li><a href="#org4610c94">Prevention</a></li>
</ul>
</li>
<li><a href="#orgf23af42">7. Diagnosis, treatment and prevention of galactosemia</a>
<ul>
<li><a href="#orgdc7f799">Diagnosis</a></li>
<li><a href="#org9247b83">Treatment</a></li>
<li><a href="#org7303f13">Prevention</a></li>
</ul>
</li>
<li><a href="#orgdc81996">8. Diagnosis, treatment and prevention of hereditary hypercholesterolemia</a>
<ul>
<li><a href="#org647dba6">Diagnosis</a></li>
<li><a href="#org04117f6">Treatment</a></li>
<li><a href="#org3a3dfb4">Prevention</a></li>
</ul>
</li>
<li><a href="#org477f576">9. Diagnosis, treatment and prevention of Huntington’s disease</a>
<ul>
<li><a href="#org44139d0">Diagnosis</a></li>
<li><a href="#orgea54765">Treatment</a></li>
<li><a href="#org927d406">Prevention</a></li>
</ul>
</li>
<li><a href="#org25b0e07">10. Diagnosis, treatment and prevention of myotonic dystrophy</a>
<ul>
<li><a href="#org3c5c83b">Diagnosis</a></li>
<li><a href="#orge3e9e4e">Treatment</a></li>
<li><a href="#orgbb7e0a3">Prevention</a></li>
</ul>
</li>
<li><a href="#org584d823">11. Diagnosis, treatment and prevention of FMR1 associated diseases</a>
<ul>
<li><a href="#org88982c0">Associated diseases</a></li>
<li><a href="#orgac31341">Diagnosis</a></li>
<li><a href="#orgc14b0fe">Treatmen</a></li>
</ul>
</li>
<li><a href="#orga1a564e">12. Diagnosis, treatment and prevention of OI type I and type II</a>
<ul>
<li><a href="#orgf661d14">Diagnosis</a></li>
<li><a href="#org96065f9">Treatment</a></li>
<li><a href="#org6f630e1">Prevention</a></li>
</ul>
</li>
<li><a href="#orgda07608">13. Diagnosis, treatment and prevention of Marfan syndrome</a>
<ul>
<li><a href="#orgc610636">Diagnosis</a></li>
<li><a href="#org3971039">Treatment</a></li>
<li><a href="#org496f210">Prevention</a></li>
</ul>
</li>
<li><a href="#org58ba7dd">14. Diagnosis, treatment and prevention of SMA</a>
<ul>
<li><a href="#org0d90482">Diagnosis</a></li>
<li><a href="#org56bafb6">Treatment</a></li>
<li><a href="#orgd253b3e">Prevention</a></li>
</ul>
</li>
<li><a href="#orga4c11fc">15. Diagnosis, treatment and prevention of Duchenne / Becker muscular dystrophy</a>
<ul>
<li><a href="#org909e5d4">Diagnosis</a></li>
<li><a href="#orgd6c1c9c">Treatment</a></li>
<li><a href="#orgd82e2c0">Prevention</a></li>
</ul>
</li>
<li><a href="#org15b5e6e">16. Diagnosis, treatment and prevention of mitochondrial diseases - LHON</a>
<ul>
<li><a href="#org8977422">Diagnosis</a></li>
<li><a href="#orge204784">Treatment</a></li>
<li><a href="#org72919e5">Prevention</a></li>
</ul>
</li>
<li><a href="#orgb09dc16">17. Balanced karyotype - Robertsonian and reciprocal translocations. Associated risks.</a>
<ul>
<li><a href="#org10f5e73">Robertsonian translocations</a></li>
<li><a href="#org20e4bdd">Reciprocal translocations</a></li>
</ul>
</li>
<li><a href="#org81cf60a">18. Diagnosis, treatment and prevention of Down syndrome.Cytogenetic forms and recurrence risk assessment</a>
<ul>
<li><a href="#orgee6cfe4">Diagnosis</a></li>
<li><a href="#org115326c">Treatment</a></li>
<li><a href="#org219d966">Prevention</a></li>
<li><a href="#orgaa74362">Cytogenetic Forms</a></li>
<li><a href="#org5ec678a">Recurrence Risk Assessment</a></li>
</ul>
</li>
<li><a href="#org85696fe">19. Diagnosis, treatment and prevention of Patau syndrome</a>
<ul>
<li><a href="#org4a3f812">Diagnosis</a></li>
<li><a href="#org8ca48cb">Treatment:</a></li>
<li><a href="#orga13d0c1">Prevention:</a></li>
</ul>
</li>
<li><a href="#orgaee4920">20. Diagnosis, treatment and prevention of Edwards syndrome</a>
<ul>
<li><a href="#org69f229b">Diagnosis</a></li>
<li><a href="#org35094f0">Treatment</a></li>
<li><a href="#org819e271">Prevention</a></li>
</ul>
</li>
<li><a href="#orgd72bfe8">21. Diagnosis, treatment and prevention of Turner syndrome and its variants</a>
<ul>
<li><a href="#org0a329e2">Diagnosis</a></li>
<li><a href="#org9d2fb55">Treatment</a></li>
<li><a href="#orgd90d27d">Prevention</a></li>
</ul>
</li>
<li><a href="#org146c535">22. Diagnosis, treatment and prevention of Klinefelter syndrome</a>
<ul>
<li><a href="#orge7d8b52">Diagnosis</a></li>
<li><a href="#org08a70af">Treatment</a></li>
<li><a href="#orga9fa50f">Prevention</a></li>
</ul>
</li>
<li><a href="#orgaebc6df">23. Diagnosis, treatment, risk assessment and prevention of Prader-Willi syndrome</a>
<ul>
<li><a href="#orgd99b646">Diagnosis</a></li>
<li><a href="#org7931545">Treatment</a></li>
<li><a href="#org3ef6038">Prevention</a></li>
</ul>
</li>
<li><a href="#org39b9c5d">24. Diagnosis, treatment, risk assessment and prevention of Angelman syndrome</a>
<ul>
<li><a href="#org559ea20">Diagnosis</a></li>
<li><a href="#org505f910">Treatment</a></li>
<li><a href="#org949471b">Prevention</a></li>
</ul>
</li>
<li><a href="#orgb0159c7">25. Diagnosis, treatment, risk assessment and prevention of DiGeorge syndrome</a>
<ul>
<li><a href="#org1cb7866">Diagnosis</a></li>
<li><a href="#org6e8450e">Treatment</a></li>
<li><a href="#orgf6ed09e">Prevention</a></li>
</ul>
</li>
<li><a href="#org4963c2c">26. Diagnosis, treatment, risk assessment and prevention of Williams-Boyren syndrome</a>
<ul>
<li><a href="#orga1482b1">Diagnosis</a></li>
<li><a href="#org8a33fb1">Treatment</a></li>
<li><a href="#orgf550b68">Prevention</a></li>
</ul>
</li>
<li><a href="#org78a8cb2">27. Diagnosis, treatment, risk assessment and prevention of Familial adenomatous polyposis</a>
<ul>
<li><a href="#org566e438">Diagnosis</a></li>
<li><a href="#org5d1e7fc">Treatment</a></li>
<li><a href="#org24ea778">Risk assessment</a></li>
<li><a href="#org3a71d23">Prevention</a></li>
</ul>
</li>
<li><a href="#org1ce273b">28. Diagnosis, treatment, risk assessment and prevention of Lynch syndrome</a>
<ul>
<li><a href="#org1b3892d">Diagnosis</a></li>
<li><a href="#orgcd45f2a">Treatment</a></li>
<li><a href="#org327804f">Risk assessment &amp; Prevention</a></li>
</ul>
</li>
<li><a href="#org463be55">29. Diagnosis, treatment, risk assessment and prevention of BRCA 1 and 2 associated inherited breast and ovarian cancer</a>
<ul>
<li><a href="#org14a90db">Diagnosis</a></li>
<li><a href="#orga1bcf7c">Treatment</a></li>
<li><a href="#org58394b0">Risk assessment &amp; prevention</a></li>
</ul>
</li>
<li><a href="#orge296bec">30. Genetic markers for targeted therapy in breast cancer</a></li>
<li><a href="#org1ad6e90">31. Genetic markers for targeted therapy in CRC</a></li>
<li><a href="#org967030b">32. Genetic Markers for Targeted Therapy at the NSCLC</a></li>
<li><a href="#org33408a2">33. Genetic markers for targeted therapy in CML</a></li>
<li><a href="#orge0b3816">34. Indications and prenatal and pre-implantation diagnosis</a></li>
</ul>
</div>
</div>

<div id="outline-container-orgb64afda" class="outline-2">
<h2 id="orgb64afda"><a href="https://muspenguins.github.io">Home Page</a></h2>
</div>
<div id="outline-container-orgfa071a2" class="outline-2">
<h2 id="orgfa071a2">Recommended resources</h2>
<div class="outline-text-2" id="text-orgfa071a2">
<ul class="org-ul">
<li><a href="https://zlibrary.to/pdfs/emerys-elements-of-medical-genetics-0">Emery's Elements Of Medical Genetics</a></li>
<li><a href="https://zlibrary.to/pdfs/principles-of-genetics">Principles Of Genetics</a></li>
<li>Department:
<ul class="org-ul">
<li><a href="https://drive.google.com/drive/folders/1WJJ6P60zXlDY7eiFd3UHQ4ZICzG0wgUd">Google Drive</a></li>
<li><a href="https://www.facebook.com/profile.php?id=100048659782406">facebook</a></li>
<li>medgenetics@medfac.mu-sofia.bg</li>
<li>m.mihaylova@medfac.mu-sofia.bg</li>
<li>medgenetics@medfac.mu-sofia.bg</li>
<li>vdamyanova@medfac.mu-sofia.bg</li>
<li>rada.staneva@medfac.mu-sofia.bg</li>
</ul></li>
<li><a href="https://ghr.nlm.nih.gov/">Genetics Home Reference</a></li>
</ul>
</div>
</div>

<div id="outline-container-org3fad9f1" class="outline-2">
<h2 id="org3fad9f1">1. Building a pedigree</h2>
<div class="outline-text-2" id="text-org3fad9f1">
<p>
A pedigree is a graphical representation of a person's family medical history that is used to identify patterns of inheritance and to assess the risk of a genetic condition running in a family.
</p>

<p>
Building a pedigree involves gathering information about a person's family medical history and using symbols to represent family members and their relationships to each other.
</p>

<p>
Here is an example of how to build a pedigree:
</p>

<ul class="org-ul">
<li>Identify the proband: The proband is the individual in the family who is affected by a genetic condition or is seeking information about their risk of developing a genetic condition.</li>

<li>Gather information: Collect information about the health of family members, including any genetic conditions that run in the family, the age of onset, and the specific symptoms or complications associated with the condition.</li>

<li>Draw the pedigree: Use symbols to represent family members and their relationships to each other. For example, a square can be used to represent a male, a circle can be used to represent a female, and a horizontal line can be used to connect a parent to a child.</li>

<li>Identify affected individuals: Use a filled-in symbol to represent individuals who are affected by a genetic condition.</li>

<li>Identify the mode of inheritance: Use specific symbols or colors to indicate the mode of inheritance, such as an "A" for autosomal dominant or an "X" for X-linked.</li>

<li>Add information about the proband: Use a double-lined symbol to represent the proband and add information about their specific genetic condition or test results.</li>

<li>Label the pedigree: Add labels to the pedigree, such as the names of family members and their ages, to make it easier to understand.</li>
</ul>
</div>
</div>
<div id="outline-container-orgbc868c9" class="outline-2">
<h2 id="orgbc868c9">2. Genetic anamnesis</h2>
<div class="outline-text-2" id="text-orgbc868c9">
<p>
Genetic anamnesis is the process of gathering information about a person's family medical history in order to identify any inherited genetic conditions or inherited risk factors for certain diseases.
</p>

<p>
The information gathered during a genetic anamnesis is used to assess an individual's risk of developing a genetic disorder and to make informed decisions about genetic testing and preventive measures.
</p>

<p>
The process of genetic anamnesis typically involves:
</p>

<ul class="org-ul">
<li>Taking a detailed family medical history: This includes asking questions about the health of family members, including any genetic conditions that run in the family, age of onset, and the specific symptoms or complications associated with the condition.</li>

<li>Identifying patterns of inheritance: Genetic conditions can be inherited in different patterns, such as autosomal dominant, autosomal recessive, or X-linked. Understanding the pattern of inheritance can help to predict the risk of a genetic condition in family members.</li>

<li>Assessing risk: Based on the information gathered during the genetic anamnesis, an individual's risk of developing a genetic condition can be assessed. This information can be used to make decisions about genetic testing and preventive measures.</li>

<li>Genetic Counseling: Genetic counseling is recommended after genetic anamnesis to give individuals and their families the opportunity to discuss the risks and benefits of genetic testing and to make informed decisions about their health care.</li>
</ul>

<p>
It is important to note that genetic anamnesis is not only important for identifying inherited genetic conditions but also for identifying predisposition to common diseases such as cancer, heart disease, and diabetes.
</p>
</div>
</div>
<div id="outline-container-org20e6b73" class="outline-2">
<h2 id="org20e6b73">3. Determining type of inheritance and risk calculation in AR, AD, XD, XR, mitochondrial inheritance</h2>
<div class="outline-text-2" id="text-org20e6b73">
<p>
The type of inheritance refers to the pattern in which a genetic trait or disorder is passed down from one generation to the next. The five main types of inheritance are
</p>
<ul class="org-ul">
<li><b>Autosomal dominant (AD) inheritance</b>: This type of inheritance occurs when a gene located on one of the autosomes (non-sex chromosomes) is dominant and only one copy of the gene is needed to express the trait or disorder. If a person inherits the gene from one parent, they will have the condition. The risk of an offspring inheriting the condition is 50% for each pregnancy.</li>

<li><b>Autosomal recessive (AR) inheritance</b>: This type of inheritance occurs when a gene located on one of the autosomes is recessive and two copies of the gene are needed to express the trait or disorder. If a person inherits one copy of the gene from each parent, they will not have the condition, but they will be a carrier of the gene. The risk of an offspring inheriting the condition is 25% for each pregnancy if both parents are carriers of the gene.</li>

<li><b>X-linked dominant (XD) inheritance</b>: This type of inheritance occurs when a gene located on the X chromosome is dominant. Females have two X chromosomes, while males have one X and one Y chromosome. Females are more likely to be affected than males. The risk of an offspring inheriting the condition is 50% for each pregnancy if the mother is affected.</li>

<li><b>X-linked recessive (XR) inheritance</b>: This type of inheritance occurs when a gene located on the X chromosome is recessive. Males are more likely to be affected than females because they only have one X chromosome. The risk of an offspring inheriting the condition is 50% for each pregnancy if the father is affected.</li>

<li><b>Mitochondrial inheritance</b>: This type of inheritance occurs when a gene located in the mitochondria, the organelles that produce energy for the cell, is passed down from the mother. The risk of an offspring inheriting the condition is 100% if the mother is affected, as all of the egg's mitochondria are passed on to the offspring.</li>
</ul>

<p>
In terms of risk calculation, in AD inheritance the risk of an offspring inheriting the condition is 50% for each pregnancy. In AR inheritance the risk of an offspring inheriting the condition is 25% if both parents are carriers. For XD and XR inheritance the risk of an offspring inheriting the condition is 50% if the mother or father is affected respectively. In mitochondrial inheritance the risk of an offspring inheriting the condition is 100% if the mother is affected.
</p>
</div>
</div>
<div id="outline-container-org882e90a" class="outline-2">
<h2 id="org882e90a">4. Diagnosis, treatment and prevention of beta-thalassemia major. Heterozygous carrier screening - beta-thalassemia minor</h2>
<div class="outline-text-2" id="text-org882e90a">
<p>
Beta-thalassemia is caused by mutations in the HBB gene, which provides instructions for making the beta-globin subunit of hemoglobin, a protein in red blood cells that carries oxygen throughout the body.
</p>
<ul class="org-ul">
<li>The HBB gene is located on the short arm (p) of chromosome 11, specifically on position 11p15.5.</li>
<li>Hemoglobin, a protein in red blood cells, is made up of two alpha-globin and two beta-globin subunits.</li>
</ul>

<p>
Beta-thalassemia occurs due to a genetic defect in one or both copies of the HBB gene that impairs the production of beta-globin. This leads to a shortage of beta-globin, which in turn causes the characteristic anemia and other symptoms seen in individuals with beta-thalassemia.
</p>


<p>
<i>The disorder is characterized by severe anemia and a variety of symptoms including fatigue, weakness, growth delays, and bone deformities.</i>
</p>
</div>

<div id="outline-container-orgfe4ef8a" class="outline-3">
<h3 id="orgfe4ef8a">Beta thalessemia major vs minor</h3>
<div class="outline-text-3" id="text-orgfe4ef8a">
<p>
The main difference between the two forms is the severity of the symptoms and the level of anemia.
</p>

<p>
Beta-thalassemia major, <i>also known as Cooley's anemia</i>, is the most severe form of the disorder.
</p>
<ul class="org-ul">
<li>It is caused by two copies of the HBB gene containing the mutation.</li>
<li>As a result, the body produces very little or no functional beta-globin.</li>
<li>This leads to a severe shortage of functional hemoglobin, causing severe anemia, fatigue, weakness, growth delays, and bone deformities.</li>
</ul>

<p>
Beta-thalassemia major is typically diagnosed in infancy or early childhood and requires regular blood transfusions for survival.
</p>

<p>
Beta-thalassemia minor, also known as thalassemia trait or heterozygous beta-thalassemia,
</p>
<ul class="org-ul">
<li>caused by a mutation in only one copy of the HBB gene.</li>
<li>The body produces some functional beta-globin, but not enough to meet the body's needs.</li>
<li>As a result, individuals with this form of the disorder have mild to moderate anemia. They typically do not have any symptoms and only require treatment if they develop severe anemia. They can be carriers and passing on the gene to their children.</li>
</ul>

<p>
<i>In summary, beta-thalassemia major is a severe form of the disorder that causes severe anemia and various symptoms, and requires regular blood transfusions for survival. Beta-thalassemia minor is a mild form of the disorder that causes mild to moderate anemia and typically does not require treatment.</i>
</p>
</div>
</div>
<div id="outline-container-orgb947afe" class="outline-3">
<h3 id="orgb947afe">Heterozygous carrier screening</h3>
<div class="outline-text-3" id="text-orgb947afe">
<ul class="org-ul">
<li>Heterozygous carrier screening is a genetic testing process that is used to identify individuals who carry one copy of a disease-causing mutation.</li>
<li>These individuals, known as heterozygous carriers, typically do not have any symptoms of the disorder themselves, but they can pass the mutation on to their children, putting them at risk of developing the disorder.</li>

<li>Heterozygous carrier screening typically involves a blood test or a saliva sample that is analyzed for the presence of specific genetic mutations associated with a particular disorder.</li>
<li>The testing process usually involves PCR (polymerase chain reaction) to amplifying the specific region of the gene to detect any variations, followed by Sanger sequencing or Next-generation sequencing (NGS) to determine the nucleotide sequence of the gene.</li>
</ul>

<p>
<i>The screening is offered to people of certain ethnic backgrounds where the incidence of certain disorders is more common. For example, in the case of beta-thalassemia, carrier screening is offered to individuals of Mediterranean, African, or Southeast Asian descent, where the disorder is prevalent.</i>
</p>
</div>
</div>
<div id="outline-container-orgd58e582" class="outline-3">
<h3 id="orgd58e582">Diagnosis</h3>
<div class="outline-text-3" id="text-orgd58e582">
<p>
<i>Diagnosis of beta-thalassemia major typically involves a combination of blood tests and genetic testing.</i>
</p>
<ul class="org-ul">
<li>Blood tests such as complete blood count (CBC) and hemoglobin electrophoresis can reveal low hemoglobin levels and an abnormal hemoglobin pattern, while genetic testing can confirm the presence of a beta-thalassemia mutation.
<ul class="org-ul">
<li>Signs and symptoms include pale skin, fatigue, weakness, and slow growth.</li>
<li>A complete blood count (CBC) will show low levels of hemoglobin and red blood cells.</li>
<li>A hemoglobin electrophoresis test can confirm the diagnosis by showing low levels of hemoglobin A (the most common form of hemoglobin) and high levels of hemoglobin F (a fetal form of hemoglobin).</li>
<li>Genetic testing can also be used to confirm the diagnosis.</li>
</ul></li>
</ul>
</div>
</div>
<div id="outline-container-orgcf6ab35" class="outline-3">
<h3 id="orgcf6ab35">Treatment</h3>
<div class="outline-text-3" id="text-orgcf6ab35">
<p>
Treatment for beta-thalassemia major typically involves regular blood transfusions to replace the missing hemoglobin, as well as iron chelation therapy to remove the excess iron that builds up in the body as a result of the transfusions.
</p>
<ul class="org-ul">
<li>Additionally, regular monitoring for complications of the disease, such as bone deformities and growth delays, is necessary.</li>

<li>A cure for beta-thalassemia major exists with Bone marrow transplantation(BMT) from a matched donor.</li>
</ul>
<p>
<i>Also, gene therapy is a potential treatment for the disease as well, but it is still considered experimental at this time.</i>
</p>

<ul class="org-ul">
<li>Beta thalessemia minor requires no treatment, but patients can pass the mutation on to their children</li>
</ul>
</div>
</div>
<div id="outline-container-org7d10523" class="outline-3">
<h3 id="org7d10523">Prevention</h3>
<div class="outline-text-3" id="text-org7d10523">
<p>
Beta-thalassemia major begins with identifying individuals who are carriers of the disease-causing mutation and providing genetic counseling and prenatal testing to families at risk.
</p>
<ul class="org-ul">
<li>In carrier couples, prenatal diagnosis is possible in the form of chorionic villus sampling or amniocentesis.</li>
</ul>
</div>
</div>
</div>

<div id="outline-container-org77b0176" class="outline-2">
<h2 id="org77b0176">5. Diagnosis,treatment and prevention of cystic fibrosis</h2>
<div class="outline-text-2" id="text-org77b0176">
<ul class="org-ul">
<li>Cystic fibrosis (CF) is a genetic disorder that affects the respiratory, digestive, and reproductive systems.</li>
<li>It is caused by mutations in the CFTR gene(located on chromosome 7, 7q31.2), which provides instructions for making a protein that regulates the movement of salt and water in and out of cells.</li>
</ul>
</div>

<div id="outline-container-orgc067413" class="outline-3">
<h3 id="orgc067413">Diagnosis</h3>
<div class="outline-text-3" id="text-orgc067413">
<p>
Diagnosis of cystic fibrosis typically involves a combination of tests, including:
</p>
<ul class="org-ul">
<li>Sweat test: The most common diagnostic test for CF, which measures the amount of salt in a person's sweat. Individuals with CF typically have higher levels of salt in their sweat than those without the disorder.</li>
<li>Genetic testing: Blood test that can identify the presence of specific genetic mutations associated with CF.</li>
<li>Lung function test: To measure the amount of air a person can inhale and exhale, and how quickly they can exhale.</li>
</ul>
<p>
Imaging studies: such as a chest X-ray or CT scan, to evaluate the lungs and any infections or blockages.
</p>
</div>
</div>
<div id="outline-container-org54f06a5" class="outline-3">
<h3 id="org54f06a5">Treatment</h3>
<div class="outline-text-3" id="text-org54f06a5">
<p>
Treatment for cystic fibrosis typically involves a multidisciplinary approach, including:
</p>
<ul class="org-ul">
<li>Medications: such as antibiotics to fight respiratory infections and bronchodilators to open up airways.</li>
<li>Airway clearance techniques: such as chest physical therapy or using a device called an airway clearance vest to help loosen and remove mucus from the lungs.</li>
<li>Nutritional support: people with CF often have difficulty absorbing nutrients from food due to problems with the pancreas, this can be treated with nutritional supplements or with a tube feeding.</li>
<li>Surgery: in some cases, surgery may be needed to remove infected or blocked airways, or to repair defects in the reproductive system.</li>
</ul>
</div>
</div>
<div id="outline-container-orgefc461d" class="outline-3">
<h3 id="orgefc461d">Prevention</h3>
<div class="outline-text-3" id="text-orgefc461d">
<ul class="org-ul">
<li>Prevention of cystic fibrosis starts with identifying individuals who are carriers of the disease-causing mutation and providing genetic counseling and prenatal testing to families at risk.</li>
<li>Carrier screening is usually offered to couples planning a pregnancy or considering in-vitro fertilization (IVF), where one or both members of the couple have a family history of the disorder or belong to an ethnic group where the incidence of the disorder is higher.</li>
<li>Prenatal diagnosis is possible with chorionic villus sampling (CVS) or amniocentesis, and can confirm whether a developing fetus has CF, or it is a carrier of the disorder.</li>
</ul>

<p>
<i>Additionally, a Newborn screening program is also in place in many countries, to early identify the disorder in infants and start treatment as soon as possible.</i>
</p>
</div>
</div>
</div>
<div id="outline-container-orge9d5616" class="outline-2">
<h2 id="orge9d5616">6. Diagnosis, treatment and prevention of PKU</h2>
<div class="outline-text-2" id="text-orge9d5616">
<ul class="org-ul">
<li>Phenylketonuria (PKU) is a genetic disorder caused by a deficiency in the enzyme phenylalanine hydroxylase (PAH), which is responsible for converting the amino acid phenylalanine (Phe) to tyrosine.</li>
<li><i>A build-up of Phe in the blood, also called hyperphenylalaninemia (HPA), can lead to severe neurological damage if left untreated</i>.</li>
<li>It is an autosomal recessive disorder, <i>which means an individual must inherit two copies of the defective gene (one from each parent) to have the disorder.</i></li>
<li>The gene involved in Phenylketonuria (PKU) is the phenylalanine hydroxylase (PAH) gene. PAH is located on chromosome 12, specifically on the short arm of chromosome 12 (12p12.2)</li>
</ul>
</div>
<div id="outline-container-org4b9dbd2" class="outline-3">
<h3 id="org4b9dbd2">Diagnosis</h3>
<div class="outline-text-3" id="text-org4b9dbd2">
<ul class="org-ul">
<li>PKU is usually diagnosed at birth by newborn screening.</li>
<li>The screening test measures the level of Phe in the blood.</li>
<li>If the level is high, a confirmatory test is done to confirm the diagnosis.</li>
<li>PKU can also be diagnosed later in life if symptoms develop or in cases of missed diagnosis at birth.</li>
</ul>
</div>
</div>

<div id="outline-container-org3a3109c" class="outline-3">
<h3 id="org3a3109c">Characteristics</h3>
<div class="outline-text-3" id="text-org3a3109c">
<ul class="org-ul">
<li>Symptoms of PKU can include intellectual disability, behavioral problems, seizures, eczema, and a musty or mousy odor of the skin, breath, and urine due to the buildup of a substance called phenylacetate.</li>
<li>If PKU is not treated from an early age, it can lead to severe neurological damage.</li>
</ul>
</div>
</div>

<div id="outline-container-orgcb019bb" class="outline-3">
<h3 id="orgcb019bb">Treatment</h3>
<div class="outline-text-3" id="text-orgcb019bb">
<p>
Treatment for PKU involves a diet that is low in Phe, along with supplements of other amino acids.
</p>
<ul class="org-ul">
<li>The diet is usually carefully planned out by a specialized medical team or a dietitian and monitored regularly.</li>
<li>Blood tests are done periodically to measure Phe and tyrosine levels, and adjust the diet accordingly.</li>
<li>Patients with PKU also need to be careful of some food and drinks which contains aspartame and phenylalanine as a sweetener.</li>
</ul>
</div>
</div>

<div id="outline-container-org4610c94" class="outline-3">
<h3 id="org4610c94">Prevention</h3>
<div class="outline-text-3" id="text-org4610c94">
<p>
PKU can be prevented through genetic counseling and prenatal testing.
</p>
<ul class="org-ul">
<li>Couples planning to have a child can be screened for the genetic mutation that causes PKU, and if both partners are carriers, prenatal testing can be done to determine whether the fetus has PKU.</li>
</ul>
</div>
</div>
</div>
<div id="outline-container-orgf23af42" class="outline-2">
<h2 id="orgf23af42">7. Diagnosis, treatment and prevention of galactosemia</h2>
<div class="outline-text-2" id="text-orgf23af42">
<p>
Galactosemia is an inherited disorder in which the body is unable to properly metabolize the sugar galactose, which is one of the components of lactose, the sugar found in milk and other dairy products.
</p>

<p>
The disorder is caused by a deficiency in one of the three enzymes responsible for the metabolism of galactose: galactose-1-phosphate uridyltransferase (GALT), galactokinase (GALK), or UDP-galactose 4-epimerase (GALE).
</p>

<ul class="org-ul">
<li>Galactosemia is inherited in an autosomal recessive pattern, meaning that an individual must inherit two copies of the defective gene (one from each parent) to have the disorder.</li>
<li>The genes affected in Galactosemia are GALT, GALK and GALE, which are located on chromosome 9, chromosome 5 and chromosome 1 respectively.</li>
<li>GALT is located on the long arm of chromosome 9 (9q34.2), GALK is located on the long arm of chromosome 5 (5q31.1) and GALE is located on the long arm of chromosome 1 (1p31).</li>
<li>Each of these genes encode for the enzymes that are responsible for the metabolism of galactose, when mutations occur in these genes it leads to deficiency of the respective enzyme and causes Galactosemia.</li>
</ul>
</div>
<div id="outline-container-orgdc7f799" class="outline-3">
<h3 id="orgdc7f799">Diagnosis</h3>
<div class="outline-text-3" id="text-orgdc7f799">
<p>
<b>Methods of diagnosis include:</b>
</p>
<ul class="org-ul">
<li>Newborn screening: In most countries, newborns are screened for galactosemia using a blood test. This test can detect the disorder before symptoms appear.</li>

<li>Clinical evaluation: If a newborn does not undergo screening or if the screening results are inconclusive, a physician may suspect galactosemia based on the presence of symptoms such as vomiting, diarrhea, jaundice, and failure to thrive.</li>

<li>Biochemical testing: A blood or urine test can be used to measure the levels of certain enzymes and sugars in the body, such as galactose-1-phosphate uridyltransferase (GALT), which is deficient in individuals with galactosemia.</li>

<li>Genetic testing: A genetic test can be used to confirm a diagnosis of galactosemia by identifying mutations in the GALT, GALK1, or GALE genes. This can also be used to determine the specific type of galactosemia an individual has.</li>
</ul>
</div>
</div>

<div id="outline-container-org9247b83" class="outline-3">
<h3 id="org9247b83">Treatment</h3>
<div class="outline-text-3" id="text-org9247b83">
<p>
Treatment for galactosemia involves a strict diet that is completely devoid of galactose and lactose, the sugar found in milk and other dairy products.
<i>If a galactose-free diet is not followed, it can lead to serious health problems, such as liver damage, cataracts, and developmental delays. Patients also need to be careful with medications, supplements, and other processed food that might contain lactose or galactose.</i>
</p>
</div>
</div>

<div id="outline-container-org7303f13" class="outline-3">
<h3 id="org7303f13">Prevention</h3>
<div class="outline-text-3" id="text-org7303f13">
<p>
Galactosemia can be prevented through genetic counseling and prenatal testing.
Couples planning to have a child can be screened for the genetic mutation that causes Galactosemia, and if both partners are carriers, prenatal testing can be done to determine whether the fetus has Galactosemia.
</p>
</div>
</div>
</div>
<div id="outline-container-orgdc81996" class="outline-2">
<h2 id="orgdc81996">8. Diagnosis, treatment and prevention of hereditary hypercholesterolemia</h2>
<div class="outline-text-2" id="text-orgdc81996">
<p>
Hereditary hypercholesterolemia (HH) is an inherited disorder characterized by high levels of LDL (low-density lipoprotein) cholesterol, also known as "bad" cholesterol, in the blood.
</p>
<ul class="org-ul">
<li>LDL cholesterol accumulates in the blood, leading to high levels of LDL cholesterol and a increased risk of cardiovascular disease.</li>
</ul>
<ul class="org-ul">
<li>The disorder is caused by mutations in genes involved in cholesterol metabolism, particularly those that encode for the LDL receptor (LDLR).</li>
<li>HH is inherited in an autosomal dominant pattern, meaning that an individual only needs to inherit one copy of the defective gene from one parent to have the disorder.</li>

<li>The gene affected in HH is the LDL receptor (LDLR) gene which is located on chromosome 19, specifically on the long arm of chromosome 19 (19q13.2) and it contains 18 exons.</li>
</ul>
</div>
<div id="outline-container-org647dba6" class="outline-3">
<h3 id="org647dba6">Diagnosis</h3>
<div class="outline-text-3" id="text-org647dba6">
<ul class="org-ul">
<li>Diagnosis of HH is typically made through a blood test to measure cholesterol levels.</li>
</ul>
<p>
If cholesterol levels are high and there is a family history of HH or premature cardiovascular disease, genetic testing can be done to confirm the diagnosis.
</p>
<ul class="org-ul">
<li>Genetic testing can detect mutations in the LDLR gene, as well as other genes involved in cholesterol metabolism.</li>
</ul>
</div>
</div>
<div id="outline-container-org04117f6" class="outline-3">
<h3 id="org04117f6">Treatment</h3>
<div class="outline-text-3" id="text-org04117f6">
<ul class="org-ul">
<li>Treatment for HH typically involves lifestyle changes such as a diet low in saturated and trans fats, as well as regular exercise to help lower cholesterol levels.</li>
<li>Medications such as statins, bile acid sequestrants, nicotinic acid, or PCSK9 inhibitors are also used to help lower cholesterol levels. In severe cases, cholesterol-lowering treatments such as apheresis or LDL apheresis may be needed.</li>
</ul>
</div>
</div>
<div id="outline-container-org3a3dfb4" class="outline-3">
<h3 id="org3a3dfb4">Prevention</h3>
<div class="outline-text-3" id="text-org3a3dfb4">
<p>
Prevention of HH involves genetic counseling for individuals and families with a history of the disorder. Prenatal testing, such as amniocentesis or chorionic villus sampling, can be done to determine whether a fetus has HH.
</p>

<p>
Carrier testing can also be done to determine if someone is a carrier of the HH-causing mutation, even if they do not have symptoms of the disorder.
</p>
</div>
</div>
</div>
<div id="outline-container-org477f576" class="outline-2">
<h2 id="org477f576">9. Diagnosis, treatment and prevention of Huntington’s disease</h2>
<div class="outline-text-2" id="text-org477f576">
<p>
<i>Huntington's disease (HD) is an inherited disorder that causes the progressive breakdown of nerve cells in the brain. It is characterized by symptoms such as involuntary movements, emotional disturbances, and cognitive decline.</i>
</p>

<p>
HD is caused by a genetic mutation in the huntingtin (HTT) gene, which is located on chromosome 4,
</p>
<ul class="org-ul">
<li>specifically on the short arm of chromosome 4 (4p16.3).</li>
</ul>
<p>
The HTT gene produces the huntingtin protein, which is involved in the development and function of nerve cells.
The genetic mutation that causes HD is a CAG trinucleotide repeat expansion in the HTT gene.
</p>
<ul class="org-ul">
<li>Individuals with 36 or more repeats have a high risk of developing HD, but the number of repeats does not correlate with the age of onset or progression of symptoms.</li>
</ul>

<p>
<i>It is inherited in an autosomal dominant pattern, individual needs to inherit one copy of the defective gene from one parent to have the disorder</i>
</p>
</div>
<div id="outline-container-org44139d0" class="outline-3">
<h3 id="org44139d0">Diagnosis</h3>
<div class="outline-text-3" id="text-org44139d0">
<ul class="org-ul">
<li>Diagnosis of HD is typically made by measuring the number of CAG repeats in the HTT gene and is confirmed by clinical examination and/or imaging.</li>
<li>Genetic counseling is recommended for individuals who may be at risk of inheriting HD and for those who have been diagnosed with HD.</li>
</ul>
</div>
</div>
<div id="outline-container-orgea54765" class="outline-3">
<h3 id="orgea54765">Treatment</h3>
<div class="outline-text-3" id="text-orgea54765">
<ul class="org-ul">
<li>Currently, there is no cure for HD and treatment is primarily focused on managing symptoms such as movements disorders, cognitive and emotional disturbances.</li>
<li>Medications such as tetrabenazine, deutetrabenazine, and valbenazine can be used to help with chorea (involuntary movements), and other medications such as antidepressants and antipsychotics can help with emotional and behavioral symptoms.</li>
<li>Speech and physical therapy, as well as occupational therapy, can also help improve function and quality of life.</li>
</ul>
</div>
</div>
<div id="outline-container-org927d406" class="outline-3">
<h3 id="org927d406">Prevention</h3>
<div class="outline-text-3" id="text-org927d406">
<ul class="org-ul">
<li>Prevention of HD is focused on genetic counseling and testing, as well as preconception and prenatal testing for individuals who may be at risk of inheriting HD.</li>
</ul>
</div>
</div>
</div>
<div id="outline-container-org25b0e07" class="outline-2">
<h2 id="org25b0e07">10. Diagnosis, treatment and prevention of myotonic dystrophy</h2>
<div class="outline-text-2" id="text-org25b0e07">
<p>
Myotonic dystrophy (DM) is a genetic disorder that affects muscle function and is characterized by progressive muscle weakness and wasting. There are two forms of Myotonic dystrophy, DM1 and DM2, which are caused by different genetic mutations.
</p>

<ul class="org-ul">
<li>DM1, also known as Steinert's disease, is caused by an expansion of a CTG trinucleotide repeat in the DMPK (dystrophia myotonica protein kinase) gene, which is located on chromosome 19 (19q13.3). The expansion leads to the formation of a toxic RNA that interferes with the normal functioning of other genes.</li>

<li>DM2, also known as Proximal Myotonic Myopathy (PROMM) is caused by an expansion of a CCTG trinucleotide repeat in the CNBP gene located on chromosome 3q21.</li>
</ul>

<p>
<i>Both form of myotonic dystrophy are inherited in an autosomal dominant pattern, meaning that an individual only needs to inherit one copy of the defective gene from one parent to have the disorder.</i>
</p>
</div>
<div id="outline-container-org3c5c83b" class="outline-3">
<h3 id="org3c5c83b">Diagnosis</h3>
<div class="outline-text-3" id="text-org3c5c83b">
<p>
Diagnosis of Myotonic Dystrophy typically involve a combination of clinical examination, genetic testing and electromyography (EMG) to measure the electrical activity of muscles.
</p>
<ul class="org-ul">
<li>Genetic testing can detect the specific genetic mutation in the DMPK or CNBP gene.</li>
</ul>
</div>
</div>
<div id="outline-container-orge3e9e4e" class="outline-3">
<h3 id="orge3e9e4e">Treatment</h3>
<div class="outline-text-3" id="text-orge3e9e4e">
<ul class="org-ul">
<li>There is no cure for Myotonic Dystrophy but drugs like mexiletine, fluoxetine, and clonazepam have been used to improve symptoms related to Myotonia and sleep disturbances. Physical therapy can help improve muscle function and mobility.</li>
</ul>
</div>
</div>
<div id="outline-container-orgbb7e0a3" class="outline-3">
<h3 id="orgbb7e0a3">Prevention</h3>
<div class="outline-text-3" id="text-orgbb7e0a3">
<p>
Prevention of Myotonic Dystrophy is focused on genetic counseling for individuals and families with a history of the disorder.
</p>
<ul class="org-ul">
<li>Prenatal testing, such as chorionic villus sampling or amniocentesis can be done to determine whether a fetus has Myotonic Dystrophy.</li>
<li>Carrier testing can also be done to determine if someone is a carrier of the Myotonic Dystrophy-causing mutation, even if they do not have symptoms of the disorder.</li>
</ul>
</div>
</div>
</div>
<div id="outline-container-org584d823" class="outline-2">
<h2 id="org584d823">11. Diagnosis, treatment and prevention of FMR1 associated diseases</h2>
<div class="outline-text-2" id="text-org584d823">
<p>
FMR1-associated diseases are a group of disorders caused by mutations in the FMR1 gene. The most well-known of these disorders is Fragile X syndrome (FXS), the most common form of inherited intellectual disability.
</p>

<ul class="org-ul">
<li>The FMR1 gene is located on the X chromosome at a location designated Xq27.3 and encodes for the protein Fragile X mental retardation protein (FMRP) which is essential for normal cognitive development and function.</li>
</ul>

<p>
<i>The FMR1 gene has a variable number of repeats of a trinucleotide sequence (CGG) in its promoter region, and when these repeats are too many, over 200, it leads to a condition called a full mutation and that leads to FXS. Individuals with 55-200 CGG repeats have a premutation of the FMR1 gene, which can lead to other disorders such as Fragile X-associated tremor/ataxia syndrome (FXTAS) in adult males and Fragile X-associated primary ovarian insufficiency (FXPOI) in females.</i>
</p>

<ul class="org-ul">
<li>The inheritance pattern of FMR1-associated diseases is X-linked dominant, which means that the gene is located on the X chromosome and only one copy of the gene needs to be affected to cause the disorder.
<ul class="org-ul">
<li>However, the phenotype, or the expression of the disorder, may vary among carriers of the premutation and females tend to have less severe symptoms than males.</li>
</ul></li>
</ul>
</div>
<div id="outline-container-org88982c0" class="outline-3">
<h3 id="org88982c0">Associated diseases</h3>
<div class="outline-text-3" id="text-org88982c0">
<ul class="org-ul">
<li><b>Fragile X syndrome</b>: This is the most common form of inherited intellectual disability and is caused by a mutation in the FMR1 gene that leads to the production of a non-functioning FMRP protein. Symptoms of fragile X syndrome can include intellectual disability, developmental delays, behavioral and emotional issues, and physical characteristics such as a long face, large ears, and flexible fingers.</li>
<li><b>Fragile X-associated tremor/ataxia syndrome (FXTAS)</b>: This is a late-onset disorder that affects individuals who have a premutation in the FMR1 gene. Symptoms can include tremors, ataxia (a lack of muscle coordination), and memory loss.</li>
<li><b>Fragile X-associated primary ovarian insufficiency (FXPOI)</b>: This is a disorder that affects the ovaries and can cause premature menopause. It is caused by a premutation in the FMR1 gene.</li>
<li><b>Fragile X-associated premature ovarian failure (FXFOP)</b>: This is a disorder that causes premature ovarian failure and infertility, it is caused by a full mutation in the FMR1 gene</li>
<li><b>Fragile X-associated neuropsychiatric disorders (FXAND)</b>: This is a group of disorders that can be caused by a premutation in the FMR1 gene and can include anxiety, depression, and obsessive-compulsive disorder.</li>
</ul>
</div>
</div>
<div id="outline-container-orgac31341" class="outline-3">
<h3 id="orgac31341">Diagnosis</h3>
<div class="outline-text-3" id="text-orgac31341">
<ul class="org-ul">
<li>Diagnosis of FMR1-associated diseases typically involves genetic testing to measure the number of CGG repeats in the FMR1 gene.</li>
<li>Genetic counseling is recommended for individuals who may be at risk of inheriting FMR1-associated diseases, and for those who have been diagnosed with the disorder.</li>
</ul>
</div>
</div>
<div id="outline-container-orgc14b0fe" class="outline-3">
<h3 id="orgc14b0fe">Treatmen</h3>
<div class="outline-text-3" id="text-orgc14b0fe">
<ul class="org-ul">
<li><b>There is no specific treatment for FMR1-associated disorders, but therapy and medication can help manage symptoms and improve quality of life</b></li>
</ul>

<p>
Here are some common managing treatments for each condition:
</p>

<ul class="org-ul">
<li>Fragile X syndrome: There is no cure for fragile X syndrome, but treatment can help manage symptoms and improve quality of life. Treatment options may include:
<ul class="org-ul">
<li>Behavioral and educational therapies: These can help with communication, social skills, and adaptive behaviors.</li>
<li>Medications: Certain medications can be used to manage symptoms such as anxiety, hyperactivity, and attention deficit disorder.</li>
<li>Speech and occupational therapy: These can help with language development, fine motor skills, and daily living activities.</li>
<li>Special education services: These can help children with fragile X syndrome succeed in school.</li>
</ul></li>

<li>Fragile X-associated tremor/ataxia syndrome (FXTAS): There is no specific treatment for FXTAS, but medications can be used to manage symptoms such as tremors and ataxia. Physical therapy, occupational therapy, and speech therapy can help with coordination and balance.</li>

<li>Fragile X-associated primary ovarian insufficiency (FXPOI): There is no specific treatment for FXPOI, but hormone replacement therapy can be used to manage symptoms such as hot flashes and vaginal dryness.</li>

<li>Fragile X-associated premature ovarian failure (FXFOP): There is no specific treatment for FXFOP, but assisted reproduction can be considered</li>

<li>Fragile X-associated neuropsychiatric disorders (FXAND): Treatment for FXAND may include behavioral therapy, counseling, and medication such as antidepressants, anti-anxiety drugs, and antipsychotic drugs.</li>
</ul>
</div>
</div>
</div>

<div id="outline-container-orga1a564e" class="outline-2">
<h2 id="orga1a564e">12. Diagnosis, treatment and prevention of OI type I and type II</h2>
<div class="outline-text-2" id="text-orga1a564e">
<p>
<i>Osteogenesis imperfecta (OI) is a group of genetic disorders that affects the formation of collagen in the bones. There are several types of OI, but type I and type II are the most common.</i>
</p>

<ul class="org-ul">
<li>OI type I, also known as brittle bone disease, is caused by mutations in the COL1A1 or COL1A2 genes, which are located on chromosome 17 and chromosome 7 respectively.</li>
<li>These genes encode for the pro-alpha1 and pro-alpha2 chains of type I collagen, which is the main component of bone. The mutations lead to decreased production or abnormal formation of collagen, resulting in fragile bones that are prone to fractures.</li>
</ul>

<p>
<b>OI type I is inherited in an autosomal dominant pattern, meaning that an individual only needs to inherit one copy of the defective gene from one parent to have the disorder.</b>
</p>

<ul class="org-ul">
<li>OI type II is a severe and often lethal form of the disorder. It is caused by mutations in the COL2A1 gene, which is located on chromosome 12 and encodes for the pro-alpha1 chain of type II collagen, which is also a component of bone.</li>
<li>The mutations lead to decreased production or abnormal formation of collagen, resulting in extremely fragile bones and other connective tissues and internal organs that are prone to fractures and serious complications.</li>
</ul>

<p>
<b>OI type II is inherited in an autosomal recessive pattern, meaning that an individual must inherit two copies of the defective gene (one from each parent) to have the disorder.</b>
</p>
</div>
<div id="outline-container-orgf661d14" class="outline-3">
<h3 id="orgf661d14">Diagnosis</h3>
<div class="outline-text-3" id="text-orgf661d14">
<p>
Diagnosis of OI typically involves a combination of clinical examination, genetic testing and radiological studies.
Genetic testing can detect specific genetic mutations in the COL1A1, COL1A2, or COL2A1 genes.
</p>
</div>
</div>
<div id="outline-container-org96065f9" class="outline-3">
<h3 id="org96065f9">Treatment</h3>
<div class="outline-text-3" id="text-org96065f9">
<p>
Treatment for OI typically involves a combination of physical therapy, orthopedic devices such as braces, wheelchairs, crutches, surgery to correct deformities or fractures and bisphosphonates medication to help strengthen the bones and reduce the risk of fractures.
</p>
<ul class="org-ul">
<li>Supportive care is also important for individuals with OI to help improve the quality of life and reduce the risk of complications.</li>
</ul>
</div>
</div>
<div id="outline-container-org6f630e1" class="outline-3">
<h3 id="org6f630e1">Prevention</h3>
<div class="outline-text-3" id="text-org6f630e1">
<ul class="org-ul">
<li>Prevention of OI type I and type II involves genetic counseling for individuals and families with a history of the disorder.</li>
<li>Prenatal testing, such as chorionic villus sampling or amniocentesis can be done to determine whether a fetus has OI.</li>
<li>Carrier testing can also be done to determine if someone is a carrier of the OI-causing</li>
</ul>
</div>
</div>
</div>
<div id="outline-container-orgda07608" class="outline-2">
<h2 id="orgda07608">13. Diagnosis, treatment and prevention of Marfan syndrome</h2>
<div class="outline-text-2" id="text-orgda07608">
<p>
Marfan syndrome is a genetic disorder that affects the connective tissue in the body, leading to problems in the bones, eyes, heart, and blood vessels.
</p>
<ul class="org-ul">
<li>The disorder is caused by mutations in the Fibrillin-1 (FBN1) gene, which is located on chromosome 15 (15q21.1) and encodes for the protein fibrillin-1, which is an essential component of connective tissue.
<ul class="org-ul">
<li>The mutations in the FBN1 gene lead to decreased production or abnormal formation of fibrillin-1, which affects the elasticity of connective tissue, leading to the characteristic signs and symptoms of Marfan syndrome.</li>
</ul></li>
</ul>

<p>
<i>Marfan syndrome is inherited in an autosomal dominant pattern, which means that an individual only needs to inherit one copy of the defective gene from one parent to have the disorder.
However, the specific symptoms, their severity and age of onset can vary widely among affected individuals and even among members of the same family.</i>
</p>
</div>
<div id="outline-container-orgc610636" class="outline-3">
<h3 id="orgc610636">Diagnosis</h3>
<div class="outline-text-3" id="text-orgc610636">
<ul class="org-ul">
<li>Diagnosis of Marfan syndrome typically involves a combination of physical examination, imaging studies, and genetic testing to detect mutations in the FBN1 gene.</li>
<li>Genetic counseling is recommended for individuals who may be at risk of inheriting Marfan syndrome, and for those who have been diagnosed with the disorder.</li>
</ul>
</div>
</div>
<div id="outline-container-org3971039" class="outline-3">
<h3 id="org3971039">Treatment</h3>
<div class="outline-text-3" id="text-org3971039">
<p>
<i>No real treatment, just symptomatic treatments available</i>
</p>
<ul class="org-ul">
<li>Treatment for Marfan syndrome primarily focuses on managing symptoms, preventing complications, and slowing the progression of the disorder.</li>
<li>Treatment may include medications to manage symptoms such as beta-blockers to help control heart rate, blood pressure and abnormal blood vessel growth, surgery to correct deformities and alleviate stress on the heart and blood vessels and physical therapy to help improve range of motion, muscle strength and flexibility.</li>
<li>Lifestyle changes such as avoiding contact sports and monitoring physical activities are also essential to decrease the risk of injury and complications.</li>
</ul>
</div>
</div>
<div id="outline-container-org496f210" class="outline-3">
<h3 id="org496f210">Prevention</h3>
<div class="outline-text-3" id="text-org496f210">
<p>
Prevention of Marfan syndrome is focused on genetic counseling for individuals and families with a history of the disorder.
</p>
<ul class="org-ul">
<li>Prenatal testing, such as chorionic villus sampling or amniocentesis can be done to determine whether a fetus has Marfan syndrome.</li>
<li>Carrier testing can also be done to determine if someone is a carrier of the Marfan syndrome-causing mutation, even if they do not have symptoms of the disorder.</li>
</ul>
</div>
</div>
</div>
<div id="outline-container-org58ba7dd" class="outline-2">
<h2 id="org58ba7dd">14. Diagnosis, treatment and prevention of SMA</h2>
<div class="outline-text-2" id="text-org58ba7dd">
<p>
Spinal muscular atrophy (SMA) is a genetic disorder that affects the nerve cells in the spinal cord that control muscle movement.
</p>
<ul class="org-ul">
<li>SMA is caused by mutations in the survival motor neuron 1 (SMN1) gene located on chromosome 5q13.3. This gene produces a protein called survival motor neuron (SMN), which is critical for the survival and function of motor neurons.</li>
</ul>
<ul class="org-ul">
<li>There are several types of SMA, with type 1 being the most severe form, typically presenting in infancy and characterized by severe muscle weakness, difficulty in swallowing and breathing.</li>
<li>Type 2 presents later in infancy, type 3 presents later in childhood and type 4 presents in adult and is the mildest form.</li>
</ul>

<p>
<i>SMA is inherited in an autosomal recessive pattern, which means that an individual must inherit two copies of the defective gene (one from each parent) to have the disorder.</i>
</p>
</div>
<div id="outline-container-org0d90482" class="outline-3">
<h3 id="org0d90482">Diagnosis</h3>
<div class="outline-text-3" id="text-org0d90482">
<p>
Methods used for diagnosis: 
</p>
<ul class="org-ul">
<li>Clinical evaluation: A physician may suspect SMA based on the presence of symptoms such as muscle weakness, muscle atrophy, and difficulty with movement and breathing.</li>

<li>Genetic testing: Genetic testing can be used to confirm a diagnosis of SMA by identifying mutations in the SMN1 gene. There are different types of genetic tests that can be used to detect SMA, such as PCR, MLPA, and NGS.</li>

<li>Biochemical testing: A blood test can be used to measure the levels of SMN protein in the body. Low levels of SMN protein can indicate a diagnosis of SMA.</li>

<li>Electromyography (EMG) and nerve conduction studies: These tests can measure the electrical activity in muscles and nerves, which can help diagnose SMA and monitor its progression.</li>

<li>Imaging studies: Imaging studies such as X-rays, MRI, and CT scans can be used to assess muscle and bone density, and to monitor the progression of the disease.</li>
</ul>
</div>
</div>
<div id="outline-container-org56bafb6" class="outline-3">
<h3 id="org56bafb6">Treatment</h3>
<div class="outline-text-3" id="text-org56bafb6">
<p>
Currently, there is no cure for SMA, and treatment is primarily focused on managing symptoms and slowing the progression of the disorder.
Treatment may include physical therapy and occupational therapy to help maintain muscle strength, mobility and function, and respiratory therapy to help with breathing difficulties.
<i>Some specific drugs are now available for some forms of SMA: nusinersen (Spinraza) and onasemnogene abeparvovec-xioi (Zolgensma)</i>
</p>
</div>
</div>
<div id="outline-container-orgd253b3e" class="outline-3">
<h3 id="orgd253b3e">Prevention</h3>
<div class="outline-text-3" id="text-orgd253b3e">
<ul class="org-ul">
<li>Prevention of SMA involves genetic counseling for individuals and families with a history of the disorder. Prenatal testing, such as chorionic villus sampling or amniocentesis, can be done to determine whether a fetus has SMA.</li>
<li>Carrier testing can also be done to determine if someone is a carrier of the SMA-causing mutation, even if they do not have symptoms of the disorder.</li>
</ul>
</div>
</div>
</div>
<div id="outline-container-orga4c11fc" class="outline-2">
<h2 id="orga4c11fc">15. Diagnosis, treatment and prevention of Duchenne / Becker muscular dystrophy</h2>
<div class="outline-text-2" id="text-orga4c11fc">
<p>
Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD) are both forms of muscular dystrophy that are caused by mutations in the dystrophin gene. The dystrophin gene is located on the X chromosome at Xp21.2 and encodes for the protein dystrophin, which is important for the stability and function of muscle fibers.
</p>

<ul class="org-ul">
<li>DMD is a severe form of the disorder that typically presents in early childhood and is characterized by progressive muscle weakness and wasting, with difficulty in walking and standing, and eventual loss of the ability to walk. DMD is caused by mutations in the dystrophin gene that result in the complete absence of dystrophin protein.</li>

<li>BMD, on the other hand, is a milder form of the disorder that typically presents in late childhood or early adulthood and is characterized by a slowly progressive muscle weakness. BMD is caused by mutations in the dystrophin gene that result in the production of an altered but partially functional dystrophin protein.</li>
</ul>

<p>
Both DMD and BMD are inherited in an X-linked recessive pattern, which means that the gene is located on the X chromosome and it is inherited in a recessive fashion, meaning that a person must inherit two copies of the defective gene, one from each parent, to have the disorder. Females are typically carriers of the disorder and may not have symptoms, while males are mostly affected by the disorder.
</p>
</div>
<div id="outline-container-org909e5d4" class="outline-3">
<h3 id="org909e5d4">Diagnosis</h3>
<div class="outline-text-3" id="text-org909e5d4">
<p>
Diagnosis of DMD and BMD typically involves a combination of clinical examination, genetic testing, and muscle biopsy to determine the absence or reduced level of dystrophin protein.
</p>
<ul class="org-ul">
<li>Genetic counseling is recommended for individuals who may be at risk of inheriting DMD and BMD.</li>
</ul>
</div>
</div>
<div id="outline-container-orgd6c1c9c" class="outline-3">
<h3 id="orgd6c1c9c">Treatment</h3>
<div class="outline-text-3" id="text-orgd6c1c9c">
<p>
Currently, there is <b>no cure for DMD and BMD</b>, and treatment primarily focuses on managing symptoms and slowing the progression of the disorder.
Treatment may include physical therapy, occupational therapy, and orthopedic devices such as leg braces to help maintain muscle strength and mobility. Medications such as corticosteroids can be used to slow muscle degeneration and improve muscle strength, and heart and lung problems associated with the disorder can be treated with specific medications.
</p>
</div>
</div>
<div id="outline-container-orgd82e2c0" class="outline-3">
<h3 id="orgd82e2c0">Prevention</h3>
<div class="outline-text-3" id="text-orgd82e2c0">
<p>
Prevention of DMD and BMD is focused on genetic counseling for individuals and families with a history of the disorder. Prenatal testing, such as chorionic villus sampling or amniocentesis, can be done to determine whether a fetus has DMD or BMD.
</p>

<p>
Carrier testing can also be done to determine if someone is a carrier of the DMD/BMD-causing mutation, even if they do not have symptoms of the disorder.
</p>

<p>
<i>In recent years, some new treatments have been developed for DMD such as exon skipping, Antisense oligonucleotide, which allow for the production of a functional form of dystrophin in some cases, although these treatments are not yet available for all patients and further research is needed.</i>
</p>
</div>
</div>
</div>
<div id="outline-container-org15b5e6e" class="outline-2">
<h2 id="org15b5e6e">16. Diagnosis, treatment and prevention of mitochondrial diseases - LHON</h2>
<div class="outline-text-2" id="text-org15b5e6e">
<p>
Leber's hereditary optic neuropathy (LHON) is a form of mitochondrial disease that specifically affects the optic nerve and leads to vision loss.
</p>
<ul class="org-ul">
<li>It is caused by mutations in the mitochondrial DNA (mtDNA) which is inherited maternally.
<ul class="org-ul">
<li>The most common mutations that cause LHON are in the genes for the enzymes NADH dehydrogenase subunit 4 (ND4), NADH dehydrogenase subunit 5 (ND5), and NADH dehydrogenase subunit 6 (ND6) which are located in the <b>mtDNA</b>.</li>
</ul></li>

<li>The inheritance pattern of LHON is maternally inherited, which means that the genetic defect is located in the mtDNA that is inherited only from the mother. <i>This is because the majority of mtDNA is inherited from the mother, the sperm contributes very little.</i></li>
</ul>
</div>
<div id="outline-container-org8977422" class="outline-3">
<h3 id="org8977422">Diagnosis</h3>
<div class="outline-text-3" id="text-org8977422">
<ul class="org-ul">
<li>Diagnosis of LHON typically involves a combination of clinical examination, imaging studies, and genetic testing to detect the specific mutation in the mtDNA that is causing the disorder.</li>
<li>Genetic counseling is recommended for individuals who may be at risk of inheriting LHON, and for those who have been diagnosed with the disorder.</li>
</ul>
</div>
</div>
<div id="outline-container-orge204784" class="outline-3">
<h3 id="orge204784">Treatment</h3>
<div class="outline-text-3" id="text-orge204784">
<p>
Currently, there is <b>no cure</b> for LHON, and treatment primarily focuses on managing symptoms and slowing the progression of the disorder.
</p>
<ul class="org-ul">
<li>Treatment may include vitamin supplements such as Coenzyme Q10 and L-Carnitine, and in some cases, a medication called idebenone which has been shown to be effective in improving vision in some individuals.</li>
</ul>
</div>
</div>
<div id="outline-container-org72919e5" class="outline-3">
<h3 id="org72919e5">Prevention</h3>
<div class="outline-text-3" id="text-org72919e5">
<p>
Prevention of LHON includes genetic counseling for individuals and families with a history of the disorder. Carrier testing can be done to determine if someone is a carrier of the LHON causing mutation, even if they do not have symptoms of the disorder.
</p>

<p>
It's important to note that vision loss caused by LHON is typically permanent, and there is no known way to completely prevent the disorder. However, early diagnosis and appropriate management can help to minimize the impact of the disorder on an individual's life and prevent complications.
</p>

<p>
<i>As LHON is caused by genetic mutations in the mitochondria which are organelles that play a key role in producing energy for the cell, there is a lot of ongoing research to understand the pathology of LHON and to find new treatments. Some potential therapies under investigation include gene therapy, cell transplantation, and antioxidant treatment.</i>
</p>
</div>
</div>
</div>
<div id="outline-container-orgb09dc16" class="outline-2">
<h2 id="orgb09dc16">17. Balanced karyotype - Robertsonian and reciprocal translocations. Associated risks.</h2>
<div class="outline-text-2" id="text-orgb09dc16">
<p>
A balanced karyotype refers to a genetic condition in which there is a structural change in the chromosomes, but the overall number of chromosomes remains the same.
</p>
<ul class="org-ul">
<li>Two types of balanced karyotypes are <b>Robertsonian and reciprocal translocations</b>.</li>
</ul>
</div>
<div id="outline-container-org10f5e73" class="outline-3">
<h3 id="org10f5e73">Robertsonian translocations</h3>
<div class="outline-text-3" id="text-org10f5e73">
<ul class="org-ul">
<li>This type of translocation occurs when a part of one chromosome attaches to a different chromosome at a different location.</li>
<li>The most common type of Robertsonian translocation is when the short arm of chromosome 21 attaches to the long arm of chromosome 14, creating a single chromosome called "translocated chromosome 14" and deleting the short arm of chromosome 21.</li>
<li>Robertsonian translocations are usually harmless, but they can increase the risk of having a child with Down syndrome if the translocated material includes part of the chromosome 21.</li>
</ul>
</div>
</div>
<div id="outline-container-org20e4bdd" class="outline-3">
<h3 id="org20e4bdd">Reciprocal translocations</h3>
<div class="outline-text-3" id="text-org20e4bdd">
<ul class="org-ul">
<li>This type of translocation occurs when two different chromosomes break and exchange material.</li>
<li>Reciprocal translocations can be balanced or unbalanced, depending on whether the total number of chromosomes is altered.</li>
<li>Balanced reciprocal translocations do not cause any significant health problems, but they can increase the risk of having a child with chromosomal abnormalities if the translocated material includes regions that contain important genes.</li>
</ul>
</div>
</div>
</div>


<div id="outline-container-org81cf60a" class="outline-2">
<h2 id="org81cf60a">18. Diagnosis, treatment and prevention of Down syndrome.Cytogenetic forms and recurrence risk assessment</h2>
<div class="outline-text-2" id="text-org81cf60a">
<ul class="org-ul">
<li>Down syndrome, also known as Trisomy 21, is a genetic disorder caused by the presence of an extra copy of chromosome 21.
<ul class="org-ul">
<li>It is the most common chromosomal disorder and it affects 1 in every 700 live births.</li>
</ul></li>
</ul>
</div>
<div id="outline-container-orgee6cfe4" class="outline-3">
<h3 id="orgee6cfe4">Diagnosis</h3>
<div class="outline-text-3" id="text-orgee6cfe4">
<p>
Down syndrome can be diagnosed before or after birth. Some of the methods used to diagnose Down syndrome include:
</p>
<ul class="org-ul">
<li>Prenatal testing: Prenatal testing can be done during pregnancy to diagnose Down syndrome. Some methods include chorionic villus sampling (CVS), amniocentesis, and non-invasive prenatal testing (NIPT).</li>

<li>Physical examination: A physician may suspect Down syndrome based on physical characteristics such as a flat facial profile, a small head, and a protruding tongue.</li>

<li>Chromosome analysis: A sample of blood, amniotic fluid, or skin cells can be analyzed to confirm the presence of an extra copy of chromosome 21.</li>
</ul>
</div>
</div>
<div id="outline-container-org115326c" class="outline-3">
<h3 id="org115326c">Treatment</h3>
<div class="outline-text-3" id="text-org115326c">
<p>
Down syndrome is a genetic disorder that cannot be cured, but early intervention and management can help improve the quality of life of those affected. Some of the treatments include:
</p>
<ul class="org-ul">
<li>Early intervention: Early intervention programs can provide services such as speech therapy, physical therapy, and occupational therapy to help children with Down syndrome reach their full potential.</li>
<li>Special education: Children with Down syndrome may require special education services to help them succeed in school.</li>
</ul>
</div>
</div>
<div id="outline-container-org219d966" class="outline-3">
<h3 id="org219d966">Prevention</h3>
<div class="outline-text-3" id="text-org219d966">
<p>
Currently, there is no known way to prevent Down syndrome, but there are some options for individuals who are at increased risk.
</p>
<ul class="org-ul">
<li>Prenatal testing can identify Down syndrome during pregnancy, allowing parents to make informed decisions about the pregnancy.</li>
<li>Preconception counseling can provide individuals who are at increased risk of having a child with Down syndrome with information about their options and the potential risks.</li>
</ul>
</div>
</div>
<div id="outline-container-orgaa74362" class="outline-3">
<h3 id="orgaa74362">Cytogenetic Forms</h3>
<div class="outline-text-3" id="text-orgaa74362">
<ul class="org-ul">
<li>Trisomy 21: This is the most common form of Down syndrome, and it occurs when there is an extra copy of chromosome 21. This accounts for 95% of all cases.</li>

<li>Mosaicism: This occurs when there is a mixture of cells with different chromosomal makeup in the body. This accounts for 1% of cases.</li>

<li>Translocation: This occurs when a part of chromosome 21 breaks off and attaches to another chromosome. This accounts for 4% of cases.</li>
</ul>
</div>
</div>

<div id="outline-container-org5ec678a" class="outline-3">
<h3 id="org5ec678a">Recurrence Risk Assessment</h3>
<div class="outline-text-3" id="text-org5ec678a">
<p>
The risk of recurrence of Down syndrome depends on the type of Down syndrome:
</p>
<ul class="org-ul">
<li>Trisomy 21: The risk of recurrence is low, as it is not a hereditary disorder.</li>
<li>Mosaicism: The risk of recurrence is low to moderate, depending on the proportion of cells with a normal karyotype.</li>
<li>Translocation: The risk of recurrence depends on whether the translocation is inherited from a parent or if it occurred spontaneously. If it is inherited, there is a risk of recurrence in future pregnancies. If it is not inherited, the risk of recurrence is low.</li>
</ul>
</div>
</div>
</div>

<div id="outline-container-org85696fe" class="outline-2">
<h2 id="org85696fe">19. Diagnosis, treatment and prevention of Patau syndrome</h2>
<div class="outline-text-2" id="text-org85696fe">
<p>
Patau syndrome is a genetic disorder caused by the presence of an extra copy of chromosome 13.
</p>
<ul class="org-ul">
<li>It's caused by a random error in cell division called non-disjunction, <b>it is not inherited</b>.</li>
<li>It is characterized by severe developmental delays, intellectual disabilities, and multiple birth defects and has a high mortality rate.</li>
</ul>
</div>
<div id="outline-container-org4a3f812" class="outline-3">
<h3 id="org4a3f812">Diagnosis</h3>
<div class="outline-text-3" id="text-org4a3f812">
<p>
Patau syndrome can be diagnosed before or after birth. Some of the methods used to diagnose Patau syndrome include:
</p>

<ul class="org-ul">
<li>Prenatal testing: Prenatal testing can be done during pregnancy to diagnose Patau syndrome. Some methods include chorionic villus sampling (CVS), amniocentesis, and non-invasive prenatal testing (NIPT).</li>

<li>Physical examination: A physician may suspect Patau syndrome based on physical characteristics such as cleft lip, cleft palate, and low-set ears.</li>

<li>Chromosome analysis: A sample of blood, amniotic fluid, or skin cells can be analyzed to confirm the presence of an extra copy of chromosome 13.</li>
</ul>
</div>
</div>
<div id="outline-container-org8ca48cb" class="outline-3">
<h3 id="org8ca48cb">Treatment:</h3>
<div class="outline-text-3" id="text-org8ca48cb">
<p>
Patau syndrome is a genetic disorder that cannot be cured, but treatment can help manage symptoms and improve the quality of life. Treatment options may include:
</p>

<ul class="org-ul">
<li>Surgery: Surgery may be necessary for certain conditions such as cleft lip and palate, heart defects, and intestinal problems.</li>
<li>Physical and occupational therapy: These therapies can help improve motor skills and mobility.</li>
<li>Medications: Medications can be used to manage specific symptoms such as heart defects and seizures.</li>
<li>Special education services: These can help children with Patau syndrome succeed in school.</li>
</ul>
</div>
</div>

<div id="outline-container-orga13d0c1" class="outline-3">
<h3 id="orga13d0c1">Prevention:</h3>
<div class="outline-text-3" id="text-orga13d0c1">
<p>
Currently, there is no known way to prevent Patau syndrome, but there are some options for individuals who are at increased risk.
</p>
<ul class="org-ul">
<li>Prenatal testing: Prenatal testing can identify Patau syndrome during pregnancy, allowing parents to make informed decisions about the pregnancy.</li>
<li>Preconception counseling: Preconception counseling can provide individuals who are at increased risk of having a child with Patau syndrome with information about their options and the potential risks.</li>
</ul>
</div>
</div>
</div>
<div id="outline-container-orgaee4920" class="outline-2">
<h2 id="orgaee4920">20. Diagnosis, treatment and prevention of Edwards syndrome</h2>
<div class="outline-text-2" id="text-orgaee4920">
<p>
Edward syndrome, also known as trisomy 18, is a genetic disorder caused by the presence of an extra copy of chromosome 18. It's <b>caused by a random error in cell division called non-disjunction</b> and it is not inherited.
It is characterized by multiple physical and cognitive abnormalities, severe developmental delays, and a high mortality rate. The diagnosis, treatment and prevention are similar to Patau and Down Syndrome.
</p>

<p>
<i>Non-disjunction is a type of chromosomal error that occurs during cell division. The chromosomes in a cell are supposed to be distributed equally to the daughter cells during cell division, but in non-disjunction, one daughter cell gets an extra copy of a chromosome, while the other daughter cell gets one less.</i>
</p>
</div>
<div id="outline-container-org69f229b" class="outline-3">
<h3 id="org69f229b">Diagnosis</h3>
<div class="outline-text-3" id="text-org69f229b">
<p>
The diagnosis of Edward syndrome can be done through several methods, including prenatal testing, physical examination, and chromosome analysis.
</p>
<ul class="org-ul">
<li>Prenatal testing: Prenatal testing can be done during pregnancy to diagnose Edward syndrome. Some methods include chorionic villus sampling (CVS), amniocentesis, and non-invasive prenatal testing (NIPT). These tests can detect the presence of an extra copy of chromosome 18 in the fetus.</li>
<li>Physical examination: A physician may suspect Edward syndrome based on physical characteristics such as a small head, a small jaw, and a small face, low-set ears, rocker bottom feet, clenched hands with overlapping fingers, and heart defects.</li>
<li>Chromosome analysis: A sample of blood, amniotic fluid, or skin cells can be analyzed to confirm the presence of an extra copy of chromosome 18. This is done through a process called karyotyping, which involves taking a sample of cells and staining them to make the chromosomes visible under a microscope. The chromosomes are then arranged in pairs to identify any extra or missing chromosomes.</li>
</ul>
</div>
</div>
<div id="outline-container-org35094f0" class="outline-3">
<h3 id="org35094f0">Treatment</h3>
<div class="outline-text-3" id="text-org35094f0">
<p>
The treatment of Edward syndrome is primarily focused on managing symptoms and improving the quality of life.
</p>

<ul class="org-ul">
<li>Surgery: Surgery may be necessary for certain conditions such as heart defects, cleft lip and palate, and intestinal problems. These surgeries are usually performed as soon as possible after birth to improve the chances of survival and to help manage symptoms.</li>
<li>Physical and occupational therapy: These therapies can help improve motor skills and mobility. They can help to increase strength and coordination, and to promote independence.</li>
<li>Medications: Medications can be used to manage specific symptoms such as heart defects and seizures. These medications can help to improve the chances of survival and to help manage symptoms.</li>
<li>Special education services: Children with Edward syndrome may require special education services to help them succeed in school. These services may include specialized instruction, adaptive equipment, and other accommodations.</li>
<li>Palliative care: Palliative care is a type of care that is focused on relieving symptoms and improving the quality of life. This can include pain management, symptom management, and emotional support.</li>
</ul>
</div>
</div>
<div id="outline-container-org819e271" class="outline-3">
<h3 id="org819e271">Prevention</h3>
<div class="outline-text-3" id="text-org819e271">
<p>
Currently, there is no known way to prevent Edward syndrome.
However, there are some options for individuals who are at increased risk of having a child with Edward syndrome. These include:
</p>

<ul class="org-ul">
<li>Preconception counseling: Preconception counseling can provide individuals who are at increased risk of having a child with Edward syndrome with information about their options and the potential risks. A genetic counselor can explain the risks of having a child with the condition and can discuss options such as prenatal testing, adoption, and donor egg or sperm.</li>

<li>Prenatal testing: Prenatal testing can identify Edward syndrome during pregnancy, allowing parents to make informed decisions about the pregnancy. Some methods include chorionic villus sampling (CVS), amniocentesis, and non-invasive prenatal testing (NIPT). These tests can detect the presence of an extra copy of chromosome 18 in the fetus.</li>

<li>Advanced maternal age: Women who are 35 years or older at the time of delivery are at increased risk of having a child with Edward syndrome.</li>

<li>Family history: If someone in the family has a child with Edward syndrome, the risk of recurrence is higher.</li>
</ul>
</div>
</div>
</div>

<div id="outline-container-orgd72bfe8" class="outline-2">
<h2 id="orgd72bfe8">21. Diagnosis, treatment and prevention of Turner syndrome and its variants</h2>
<div class="outline-text-2" id="text-orgd72bfe8">
<p>
Turner syndrome is a genetic disorder that affects only females, caused by the absence of all or part of one of the X chromosomes.
</p>
<ul class="org-ul">
<li>It is characterized by short stature, webbed neck, a low hairline at the back of the neck, and a shield chest. Other features can include heart defects, kidney problems, and hearing loss.</li>
<li>It is not inherited, not caused by anything the parents did or did not do.</li>
<li>The diagnosis, treatment and prevention are specific to the disorder.</li>
</ul>
</div>
<div id="outline-container-org0a329e2" class="outline-3">
<h3 id="org0a329e2">Diagnosis</h3>
<div class="outline-text-3" id="text-org0a329e2">
<p>
The diagnosis of Turner syndrome can be done through a combination of physical examination, chromosomal analysis, and blood tests.
</p>

<ul class="org-ul">
<li>Physical examination: A physician may suspect Turner syndrome based on physical characteristics such as short stature, webbed neck, a low hairline at the back of the neck, and a shield chest.</li>
<li>Chromosomal analysis: A sample of blood, amniotic fluid, or skin cells can be analyzed to confirm the presence of only one X chromosome. This is done through a process called karyotyping, which involves taking a sample of cells and staining them to make the chromosomes visible under a microscope. The chromosomes are then arranged in pairs to identify any missing or extra chromosomes.</li>
<li>Blood tests: Blood tests can be used to measure levels of hormones such as estrogen and follicle-stimulating hormone (FSH). High levels of FSH may indicate that the ovaries are not functioning properly, which is a common feature of Turner syndrome.</li>
</ul>
</div>
</div>
<div id="outline-container-org9d2fb55" class="outline-3">
<h3 id="org9d2fb55">Treatment</h3>
<div class="outline-text-3" id="text-org9d2fb55">
<p>
The treatment of Turner syndrome is focused on managing symptoms and improving the quality of life. Treatment options may include:
</p>

<ul class="org-ul">
<li>Growth hormone therapy: This therapy can help increase height in girls with Turner syndrome. It is typically started around age 5 and continued until the patient reaches a near final height.</li>
<li>Estrogen replacement therapy: This therapy can help with physical development and bone health. It is typically started around age 12 or 13 and continued until the patient reaches her late teens or early twenties.</li>
<li>Surgery: Surgery may be necessary for certain conditions such as heart defects and kidney problems.</li>
<li>Speech therapy, occupational therapy, and physical therapy: These therapies can help improve communication, motor skills, and overall development.</li>
<li>Educational support: Children with Turner syndrome may require special education services to help them succeed in school.</li>
<li>Psychological support: Children and adults with Turner syndrome may benefit from psychological support and counseling to help them cope with the physical and emotional aspects of the condition.</li>
</ul>
</div>
</div>
<div id="outline-container-orgd90d27d" class="outline-3">
<h3 id="orgd90d27d">Prevention</h3>
<div class="outline-text-3" id="text-orgd90d27d">
<p>
Prevention of Turner syndrome is not currently possible as it is caused by a random event during the formation of reproductive cells or in early fetal development.
</p>

<p>
However, there are some options for individuals who are at increased risk of having a child with Turner syndrome. These include:
</p>

<ul class="org-ul">
<li>Genetic counseling: Genetic counseling can provide individuals who are at increased risk of having a child with Turner syndrome with information about their options and the potential risks. A genetic counselor can explain the risks of having a child with the condition and can discuss options such as prenatal testing, adoption, and donor egg or sperm.</li>
<li>Prenatal testing: Prenatal testing can identify Turner syndrome during pregnancy, allowing parents to make informed decisions about the pregnancy. Some methods include chorionic villus sampling (CVS), amniocentesis, and non-invasive prenatal testing (NIPT). These tests can detect the presence of only one X chromosome in the fetus.</li>
<li>Advanced maternal age: Women who are 35 years or older at the time of delivery are at increased risk of having a child with Turner syndrome.</li>
</ul>
</div>
</div>
</div>
<div id="outline-container-org146c535" class="outline-2">
<h2 id="org146c535">22. Diagnosis, treatment and prevention of Klinefelter syndrome</h2>
<div class="outline-text-2" id="text-org146c535">
<p>
Klinefelter syndrome is a genetic disorder that affects males and is caused by an extra X chromosome. Instead of the typical XY chromosomes, individuals with Klinefelter syndrome have at least one extra X chromosome (XXY, XXXY, XXXXY) which leads to a total of 47 chromosomes instead of the typical 46.
<i>In Klinefelter syndrome, the sperm or egg carries an extra X chromosome</i>
</p>
<ul class="org-ul">
<li>This extra X chromosome can lead to a variety of physical and developmental characteristics.</li>
</ul>
<p>
The most common symptoms of Klinefelter syndrome are tall stature, small testes, and difficulty with spatial perception and fine motor skills.
Other symptoms can include breast development, low muscle tone, and difficulty with language and communication. Many individuals with Klinefelter syndrome also have difficulty with spatial perception and fine motor skills, and may have learning difficulties.
</p>

<ul class="org-ul">
<li>Klinefelter syndrome is not inherited, it occurs as a random event during the formation of reproductive cells.</li>
</ul>
</div>
<div id="outline-container-orge7d8b52" class="outline-3">
<h3 id="orge7d8b52">Diagnosis</h3>
<div class="outline-text-3" id="text-orge7d8b52">
<p>
The diagnosis of Klinefelter syndrome can be done through a combination of physical examination, chromosomal analysis, and blood tests:
</p>
<ul class="org-ul">
<li>Physical examination: A physician may suspect Klinefelter syndrome based on physical characteristics such as tall stature, small testes, and breast development.</li>
<li>Chromosomal analysis: A sample of blood, amniotic fluid, or skin cells can be analyzed to confirm the presence of extra X chromosome. This is done through a process called karyotyping, which involves taking a sample of cells and staining them to make the chromosomes visible under a microscope. The chromosomes are then arranged in pairs to identify any missing or extra chromosomes.</li>
<li>Blood tests: Blood tests can be used to measure levels of testosterone and other hormones, which may be lower than normal in individuals with Klinefelter syndrome.</li>
</ul>
</div>
</div>
<div id="outline-container-org08a70af" class="outline-3">
<h3 id="org08a70af">Treatment</h3>
<div class="outline-text-3" id="text-org08a70af">
<p>
Treatment for Klinefelter syndrome is focused on managing symptoms and improving the quality of life. Treatment options may include:
</p>

<ul class="org-ul">
<li>Testosterone replacement therapy: This therapy can help with physical development and sexual function. It is typically started around puberty and continued throughout adulthood.</li>

<li>Speech therapy, occupational therapy, and physical therapy: These therapies can help improve communication, motor skills, and overall development.</li>

<li>Educational support: Children with Klinefelter syndrome may require special education services to help them succeed in school.</li>

<li>Psychological support: Children and adults with Klinefelter syndrome may benefit from psychological support and counseling to help them cope with the physical and emotional aspects of the condition.</li>

<li>Surgery: Surgery may be necessary for certain conditions such as breast development.</li>
</ul>
</div>
</div>
<div id="outline-container-orga9fa50f" class="outline-3">
<h3 id="orga9fa50f">Prevention</h3>
<div class="outline-text-3" id="text-orga9fa50f">
<p>
It is not currently possible as Klinefelter syndrome is caused by a random event during the formation of reproductive cells and it is not inherited. It is not caused by anything the parents did or did not do.
</p>
</div>
</div>
</div>
<div id="outline-container-orgaebc6df" class="outline-2">
<h2 id="orgaebc6df">23. Diagnosis, treatment, risk assessment and prevention of Prader-Willi syndrome</h2>
<div class="outline-text-2" id="text-orgaebc6df">
<p>
Prader-Willi syndrome (PWS) is a genetic disorder that affects multiple systems in the body, including growth, metabolism, and behavior. It is characterized by a combination of symptoms, including low muscle tone, short stature, developmental delays, and an insatiable appetite which can lead to obesity. Other common symptoms include small hands and feet, almond-shaped eyes, and a curved fifth finger.
</p>
<ul class="org-ul">
<li>PWS is caused by a deletion or dysfunction of a specific region on chromosome 15,specifically a region called the Prader-Willi critical region (PWCR). The PWCR is located on the long arm of chromosome 15 (15q11-q13).</li>
</ul>
</div>
<div id="outline-container-orgd99b646" class="outline-3">
<h3 id="orgd99b646">Diagnosis</h3>
<div class="outline-text-3" id="text-orgd99b646">
<ul class="org-ul">
<li>The diagnosis of Prader-Willi syndrome (PWS) is typically made based on the presence of certain clinical features such as low muscle tone, short stature, developmental delays, and an insatiable appetite which can lead to obesity.
<ul class="org-ul">
<li>Other common symptoms include small hands and feet, almond-shaped eyes, and a curved fifth finger.</li>
</ul></li>
</ul>

<p>
However, a definitive diagnosis can only be made through genetic testing. The genetic testing can confirm the absence of the genetic material from the father's chromosome 15 or detect the presence of two copies of the genetic material from the mother's chromosome 15, which confirms the diagnosis.
</p>
</div>
</div>

<div id="outline-container-org7931545" class="outline-3">
<h3 id="org7931545">Treatment</h3>
<div class="outline-text-3" id="text-org7931545">
<p>
Treatment for PWS is focused on managing symptoms and includes a combination of therapies such as:
</p>

<ul class="org-ul">
<li>Growth hormone therapy: This therapy can help with growth and development.</li>

<li>Physical therapy, occupational therapy, and speech therapy: These therapies can help improve muscle tone, fine motor skills, and communication.</li>

<li>Specialized care and education: Individuals with PWS may require specialized care and education to help them reach their full potential.</li>

<li>Support for behavior and emotional issues: Individuals with PWS may require support for behavior and emotional issues such as anxiety, depression, and obsessive-compulsive disorder.</li>

<li>Strict diet: To prevent obesity, individuals with PWS require a strict diet, including regular meals and snacks, and monitoring of calorie intake.</li>
</ul>
</div>
</div>
<div id="outline-container-org3ef6038" class="outline-3">
<h3 id="org3ef6038">Prevention</h3>
<div class="outline-text-3" id="text-org3ef6038">
<p>
Prevention of Prader-Willi syndrome (PWS) is not currently possible as it is caused by a genetic disorder that occurs as a random event during the formation of reproductive cells and it is not inherited.
However, there are some options for individuals who are at increased risk of having a child with PWS. These include:
</p>

<ul class="org-ul">
<li>Genetic counseling: Genetic counseling can provide individuals who are at increased risk of having a child with PWS with information about their options and the potential risks. A genetic counselor can explain the risks of having a child with the condition and can discuss options such as prenatal testing, adoption, and donor egg or sperm.</li>

<li>Prenatal testing: Prenatal testing can identify PWS during pregnancy, allowing parents to make informed decisions about the pregnancy. Some methods include chorionic villus sampling (CVS) and amniocentesis. These tests can detect the deletion of the genetic material from the father's chromosome 15 or detect the presence of two copies of the genetic material from the mother's chromosome 15.</li>
<li>Preimplantation genetic diagnosis (PGD): PGD is a technique used in conjunction with in-vitro fertilization (IVF) to diagnose genetic disorders in embryos before they are implanted in the uterus. This allows couples at risk of passing on PWS to have unaffected children.</li>
</ul>
</div>
</div>
</div>

<div id="outline-container-org39b9c5d" class="outline-2">
<h2 id="org39b9c5d">24. Diagnosis, treatment, risk assessment and prevention of Angelman syndrome</h2>
<div class="outline-text-2" id="text-org39b9c5d">
<p>
Angelman syndrome is a genetic disorder caused by a loss or dysfunction of a specific region on chromosome 15, specifically a region called the Angelman critical region (ACR) on the long arm of chromosome 15 (15q11-q13). This region contains several genes that play a crucial role in brain development.
</p>

<p>
The most common cause of Angelman syndrome is a deletion of the ACR on the maternal chromosome 15. In about 3-4% of cases, it is caused by a mutation in the UBE3A gene which is located within the ACR. In rare cases, it is caused by a defect in the imprinting process, which results in the paternal copy of the chromosome 15 being active instead of the maternal copy.
</p>

<p>
The clinical picture of Angelman syndrome is characterized by a combination of symptoms, including developmental delay, intellectual disability, speech impairment, and difficulty with balance and motor coordination. Other common symptoms include a characteristic facial appearance, seizures, and a happy and sociable personality.
</p>

<ul class="org-ul">
<li>Individuals with Angelman syndrome often have a unique behavioral profile, characterized by a happy and sociable demeanor, frequent smiling and laughter, and a lack of fear.</li>
</ul>
</div>
<div id="outline-container-org559ea20" class="outline-3">
<h3 id="org559ea20">Diagnosis</h3>
<div class="outline-text-3" id="text-org559ea20">
<p>
The diagnosis of Angelman syndrome can be made through a combination of clinical examination, genetic testing, and other diagnostic tests.
</p>

<ul class="org-ul">
<li>Clinical examination: A physician may suspect Angelman syndrome based on the presence of certain clinical features such as developmental delay, intellectual disability, speech impairment, and difficulty with balance and motor coordination. Other common symptoms include a characteristic facial appearance, seizures, and a happy and sociable personality.</li>

<li>Genetic testing: Genetic testing can confirm the diagnosis of Angelman syndrome. The most common genetic test is a DNA test that looks for a deletion or mutation in the UBE3A gene, which is located within the Angelman critical region (ACR) on chromosome 15. Other genetic tests such as chromosomal microarray analysis (CMA) and fluorescence in situ hybridization (FISH) can also be used to detect a deletion of the ACR.</li>
</ul>

<p>
Additional testing: Additional tests such as EEG and brain imaging studies can also be helpful in making a diagnosis of Angelman syndrome.
</p>
</div>
</div>
<div id="outline-container-org505f910" class="outline-3">
<h3 id="org505f910">Treatment</h3>
<div class="outline-text-3" id="text-org505f910">
<p>
Treatment for Angelman syndrome is focused on managing symptoms and improving the quality of life. Treatment options may include:
</p>

<ul class="org-ul">
<li>Speech and language therapy: This therapy can help with communication and language development.</li>

<li>Occupational and physical therapy: These therapies can help with motor development, balance, and coordination.</li>

<li>Special education services: Children with Angelman syndrome may require special education services to help them succeed in school.</li>

<li>Medications: Medications can be used to manage seizures and other symptoms.</li>

<li>Behavioral and psychological support: Children and adults with Angelman syndrome may benefit from psychological support and counseling to help them cope with the physical and emotional aspects of the condition.</li>

<li>Specialized care: Individuals with Angelman syndrome may require specialized care and support throughout their lifetime.</li>
</ul>
</div>
</div>
<div id="outline-container-org949471b" class="outline-3">
<h3 id="org949471b">Prevention</h3>
<div class="outline-text-3" id="text-org949471b">
<p>
Prevention of Angelman syndrome is not currently possible as it is caused by a genetic disorder that occurs as a random event during the formation of reproductive cells and it is not inherited. It is not caused by anything the parents did or did not do.
</p>

<p>
However, there are some options for individuals who are at increased risk of having a child with Angelman syndrome. These include:
</p>

<ul class="org-ul">
<li>Genetic counseling: Genetic counseling can provide individuals who are at increased risk of having a child with Angelman syndrome with information about their options and the potential risks. A genetic counselor can explain the risks of having a child with the condition and can discuss options such as prenatal testing, adoption, and donor egg or sperm.</li>

<li>Prenatal testing: Prenatal testing can identify Angelman syndrome during pregnancy, allowing parents to make informed decisions about the pregnancy. Some methods include chorionic villus sampling (CVS) and amniocentesis. These tests can detect the deletion of the genetic material from the mother's chromosome 15 or detect the presence of a mutation in the UBE3A gene.</li>

<li>Preimplantation genetic diagnosis (PGD): PGD is a technique used in conjunction with in-vitro fertilization (IVF) to diagnose genetic disorders in embryos before they are implanted in the uterus. This allows couples at risk of passing on Angelman syndrome to have unaffected children.</li>
</ul>
</div>
</div>
</div>
<div id="outline-container-orgb0159c7" class="outline-2">
<h2 id="orgb0159c7">25. Diagnosis, treatment, risk assessment and prevention of DiGeorge syndrome</h2>
<div class="outline-text-2" id="text-orgb0159c7">
<p>
DiGeorge syndrome is a genetic disorder caused by a missing piece of chromosome 22.
</p>
<ul class="org-ul">
<li>Specifically, it is caused by a deletion of a small piece of the long arm of chromosome 22, at a location designated as 22q11.2.</li>
</ul>
<p>
The clinical picture of DiGeorge syndrome can vary greatly from person to person but it is characterized by a combination of symptoms such as Congenital Heart Defects, Immune System Dysfunction, Facial Anomalies, Delays In Motor Development, Speech And Language Development, Learning Difficulties, Behavioral And Psychological Problems, And Hormonal Imbalances
</p>
</div>
<div id="outline-container-org1cb7866" class="outline-3">
<h3 id="org1cb7866">Diagnosis</h3>
<div class="outline-text-3" id="text-org1cb7866">
<ul class="org-ul">
<li>Diagnosis is made by identifying the above clinical picture. Additionally, a physical examination may reveal low levels of calcium in the blood, which is a common finding in individuals with DiGeorge syndrome.</li>
<li>However, a definitive diagnosis can only be made through genetic testing. Genetic testing such as chromosomal microarray analysis (CMA) or fluorescence in situ hybridization (FISH) can detect the deletion of the genetic material at the 22q11.2 location, which confirms the diagnosis of DiGeorge syndrome.</li>
</ul>
</div>
</div>
<div id="outline-container-org6e8450e" class="outline-3">
<h3 id="org6e8450e">Treatment</h3>
<div class="outline-text-3" id="text-org6e8450e">
<p>
Treatment for DiGeorge syndrome is typically multidisciplinary and tailored to the individual's specific symptoms and needs. Treatment options may include:
</p>

<ul class="org-ul">
<li>Surgery: Surgery may be required to correct congenital heart defects, cleft palate, or other physical anomalies.</li>

<li>Medications: Medications may be necessary to manage symptoms such as seizures, behavioral problems, and hormonal imbalances.</li>

<li>Immunotherapy: Individuals with DiGeorge syndrome may require immunotherapy to help boost their immune system and prevent recurrent infections.</li>

<li>Speech and language therapy: This therapy can help with communication and language development.</li>

<li>Occupational and physical therapy: These therapies can help with motor development, balance, and coordination.</li>

<li>Special education services: Children with DiGeorge syndrome may require special education services to help them succeed in school.</li>

<li>Behavioral and psychological support: Children and adults with DiGeorge syndrome may benefit from psychological support and counseling to help them cope with the physical and emotional aspects of the condition.</li>

<li>Specialized care: Individuals with DiGeorge syndrome may require specialized care and support throughout their lifetime.</li>
</ul>
</div>
</div>
<div id="outline-container-orgf6ed09e" class="outline-3">
<h3 id="orgf6ed09e">Prevention</h3>
<div class="outline-text-3" id="text-orgf6ed09e">
<p>
Prevention of DiGeorge syndrome is not currently possible as it is caused by a genetic disorder that occurs as a random event during the formation of reproductive cells and it is not inherited. It is not caused by anything the parents did or did not do.
However, there are some options for individuals who are at increased risk of having a child with DiGeorge syndrome. These include:
</p>

<ul class="org-ul">
<li>Genetic counseling: Genetic counseling can provide individuals who are at increased risk of having a child with DiGeorge syndrome with information about their options and the potential risks. A genetic counselor can explain the risks of having a child with the condition and can discuss options such as prenatal testing, adoption, and donor egg or sperm.</li>

<li>Prenatal testing: Prenatal testing can identify DiGeorge syndrome during pregnancy, allowing parents to make informed decisions about the pregnancy. Some methods include chorionic villus sampling (CVS) and amniocentesis. These tests can detect the deletion of the genetic material at the 22q11.2 location.</li>

<li>Preimplantation genetic diagnosis (PGD): PGD is a technique used in conjunction with in-vitro fertilization (IVF) to diagnose genetic disorders in embryos before they are implanted in the uterus. This allows couples at risk of passing on DiGeorge syndrome to have unaffected children.</li>
</ul>
</div>
</div>
</div>
<div id="outline-container-org4963c2c" class="outline-2">
<h2 id="org4963c2c">26. Diagnosis, treatment, risk assessment and prevention of Williams-Boyren syndrome</h2>
<div class="outline-text-2" id="text-org4963c2c">
<p>
Williams-Beuren syndrome (WBS) is a genetic disorder caused by a deletion of a specific region on chromosome 7, specifically a deletion of a segment of the long arm of chromosome 7, at a location designated as 7q11.23.
</p>

<ul class="org-ul">
<li>The deletion of this segment results in the loss of several genes, including those that play a crucial role in development and the regulation of the immune system and cardiovascular system.</li>
<li>The deletion of these genes leads to the characteristic symptoms seen in individuals with WBS, such as developmental delays, cardiovascular problems, and unique facial features.</li>
</ul>
</div>
<div id="outline-container-orga1482b1" class="outline-3">
<h3 id="orga1482b1">Diagnosis</h3>
<div class="outline-text-3" id="text-orga1482b1">
<p>
The diagnosis of Williams-Beuren syndrome (WBS) can be made through a combination of clinical examination, genetic testing, and other diagnostic tests.
</p>

<ul class="org-ul">
<li>Clinical examination: A physician may suspect WBS based on the presence of certain clinical features such as developmental delays, cardiovascular problems, and unique facial features.
<ul class="org-ul">
<li>Common facial features include a small upturned nose, full lips, and a small jaw. Other common symptoms include a cheerful and sociable personality, a high-pitched voice, and a curious and eager-to-learn attitude.</li>
</ul></li>

<li>Genetic testing: Genetic testing can confirm the diagnosis of WBS. The most common genetic test is a DNA test that looks for a deletion of the region on chromosome 7q11.23. Other genetic tests such as chromosomal microarray analysis (CMA) and fluorescence in situ hybridization (FISH) can also be used to detect the deletion.</li>

<li>Additional testing: Additional tests such as EEG, echocardiograms, and MRI may be used to evaluate specific symptoms and further confirm the diagnosis.</li>
</ul>
</div>
</div>
<div id="outline-container-org8a33fb1" class="outline-3">
<h3 id="org8a33fb1">Treatment</h3>
<div class="outline-text-3" id="text-org8a33fb1">
<p>
Treatment for Williams-Beuren syndrome (WBS) is typically multidisciplinary and tailored to the individual's specific symptoms and needs. Treatment options may include:
</p>

<ul class="org-ul">
<li>Cardiac care: Individuals with WBS may require ongoing care for cardiovascular problems such as supravalvular aortic stenosis (SVAS) and peripheral pulmonary stenosis (PPS). This may include surgery, medications, or other interventions.</li>

<li>Physical and occupational therapy: These therapies can help with motor development, balance, and coordination.</li>

<li>Speech and language therapy: This therapy can help with communication and language development.</li>

<li>Special education services: Children with WBS may require special education services to help them succeed in school.</li>

<li>Behavioral and psychological support: Children and adults with WBS may benefit from psychological support and counseling to help them cope with the physical and emotional aspects of the condition.</li>

<li>Specialized care: Individuals with WBS may require specialized care and support throughout their lifetime.</li>

<li>Medications: Medications may be necessary to manage symptoms such as seizures, behavioral problems, and hormonal imbalances.</li>
</ul>
</div>
</div>
<div id="outline-container-orgf550b68" class="outline-3">
<h3 id="orgf550b68">Prevention</h3>
<div class="outline-text-3" id="text-orgf550b68">
<p>
Prevention of Williams-Beuren syndrome (WBS) is not currently possible as it is caused by a genetic disorder that occurs as a random event during the formation of reproductive cells and it is not inherited. It is not caused by anything the parents did or did not do.
</p>

<p>
However, there are some options for individuals who are at increased risk of having a child with WBS. These include:
</p>

<ul class="org-ul">
<li>Genetic counseling: Genetic counseling can provide individuals who are at increased risk of having a child with WBS with information about their options and the potential risks. A genetic counselor can explain the risks of having a child with the condition and can discuss options such as prenatal testing, adoption, and donor egg or sperm.</li>

<li>Prenatal testing: Prenatal testing can identify WBS during pregnancy, allowing parents to make informed decisions about the pregnancy. Some methods include chorionic villus sampling (CVS) and amniocentesis. These tests can detect the deletion of the genetic material at the 7q11.23 location.</li>

<li>Preimplantation genetic diagnosis (PGD): PGD is a technique used in conjunction with in-vitro fertilization (IVF) to diagnose genetic disorders in embryos before they are implanted in the uterus. This allows couples at risk of passing on WBS to have unaffected children.</li>
</ul>
</div>
</div>
</div>
<div id="outline-container-org78a8cb2" class="outline-2">
<h2 id="org78a8cb2">27. Diagnosis, treatment, risk assessment and prevention of Familial adenomatous polyposis</h2>
<div class="outline-text-2" id="text-org78a8cb2">
<p>
Familial adenomatous polyposis (FAP) is a genetic disorder caused by a mutation in the APC gene, which is located on chromosome 5 (5q21-q22).
</p>
<ul class="org-ul">
<li>The APC gene provides instructions for making a protein that helps regulate cell growth and division. A mutation in this gene leads to the formation of many polyps in the colon and rectum, which can progress to colon cancer if left untreated.</li>
<li>The mutation can be inherited in an autosomal dominant pattern, meaning that an affected person has a 50% chance of passing the mutation to their children.</li>
</ul>
</div>
<div id="outline-container-org566e438" class="outline-3">
<h3 id="org566e438">Diagnosis</h3>
<div class="outline-text-3" id="text-org566e438">
<p>
The diagnosis of Familial Adenomatous Polyposis (FAP) can be made through a combination of clinical examination, genetic testing, and other diagnostic tests.
</p>

<ul class="org-ul">
<li>Clinical examination: A physician may suspect FAP based on the presence of multiple colonic adenomas and/or a family history of colorectal cancer or polyps. A physical examination may reveal multiple colonic polyps, particularly if the patient is young and has a strong family history of colorectal cancer.</li>

<li>Genetic testing: Genetic testing is the most definitive method for diagnosing FAP. The most common genetic test is a DNA test that looks for mutations in the APC gene, which is located on chromosome 5q21-q22. This test can detect the APC mutations that cause FAP with high accuracy.</li>

<li>Additional testing: Additional tests such as colonoscopy, stool-based tests, and imaging studies may be used to evaluate specific symptoms and further confirm the diagnosis.</li>
</ul>
</div>
</div>
<div id="outline-container-org5d1e7fc" class="outline-3">
<h3 id="org5d1e7fc">Treatment</h3>
<div class="outline-text-3" id="text-org5d1e7fc">
<ul class="org-ul">
<li>Surgery: Surgery is the main treatment for FAP. It involves removing the entire colon and rectum (colectomy) to prevent the development of colon cancer. This procedure is called prophylactic colectomy.</li>
</ul>
<p>
<i>The surgery may be performed in two stages, the first stage is called proctocolectomy, and it involves the removal of the rectum and the colon, and the second stage is the ileoanal anastomosis, which involves creating a pouch out of the small intestine to replace the rectum and the colon.</i>
</p>

<ul class="org-ul">
<li>Medications: Medications may be used to reduce the number of polyps in the colon and rectum, these medications include Sulindac, celecoxib, and etodolac.</li>

<li>Surveillance: Individuals with FAP should undergo regular surveillance, such as colonoscopy and stool-based tests, to detect and remove new polyps as early as possible.</li>
</ul>
</div>
</div>
<div id="outline-container-org24ea778" class="outline-3">
<h3 id="org24ea778">Risk assessment</h3>
<div class="outline-text-3" id="text-org24ea778">
<p>
Individuals with FAP have a very high risk of developing colon cancer, so it is important to identify the individuals at the highest risk of developing cancer and to implement surveillance and treatment accordingly.
</p>
</div>
</div>
<div id="outline-container-org3a71d23" class="outline-3">
<h3 id="org3a71d23">Prevention</h3>
<div class="outline-text-3" id="text-org3a71d23">
<p>
Prevention of Familial Adenomatous Polyposis (FAP) is primarily focused on detecting and removing colonic polyps before they have the opportunity to become cancerous. The most effective way to prevent colon cancer in individuals with FAP is through prophylactic colectomy, which involves removing the entire colon and rectum. This procedure can reduce the risk of colon cancer by nearly 100%.
</p>

<p>
Other options for preventing colon cancer in individuals with FAP include:
</p>

<ul class="org-ul">
<li>Surveillance: Regular surveillance, such as colonoscopy and stool-based tests, can detect and remove new polyps as early as possible. Individuals with FAP should undergo surveillance starting at a young age, typically between the ages of 10 and 12, and continue throughout their lifetime.</li>

<li>Medications: Medications such as Sulindac, celecoxib, and etodolac may be used to reduce the number of polyps in the colon and rectum.</li>

<li>Chemoprevention: Chemoprevention is the use of medications, vitamins, or other agents to reduce the risk of cancer. Some studies have suggested that the use of aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) can reduce the risk of colon cancer in individuals with FAP.</li>
</ul>
</div>
</div>
</div>
<div id="outline-container-org1ce273b" class="outline-2">
<h2 id="org1ce273b">28. Diagnosis, treatment, risk assessment and prevention of Lynch syndrome</h2>
<div class="outline-text-2" id="text-org1ce273b">
<p>
Lynch syndrome, also known as hereditary nonpolyposis colorectal cancer (HNPCC), is a genetic disorder that increases the risk of developing certain types of cancer, particularly colorectal cancer, endometrial cancer, and other cancers of the gastrointestinal tract. Lynch Syndrome is caused by a mutation in one of several genes that are responsible for repairing DNA damage, including:
</p>

<ul class="org-ul">
<li>MLH1, located on chromosome 3p22.2</li>
<li>MSH2, located on chromosome 2p16.3</li>
<li>MSH6, located on chromosome 2p16.1</li>
<li>PMS2, located on chromosome 7p22.1</li>
</ul>

<p>
Mutations in these genes lead to a defect in DNA mismatch repair, which results in an increased risk of developing cancer. Lynch syndrome is inherited in an autosomal dominant pattern, meaning that each child of an affected parent has a 50% chance of inheriting the mutation.
</p>
</div>
<div id="outline-container-org1b3892d" class="outline-3">
<h3 id="org1b3892d">Diagnosis</h3>
<div class="outline-text-3" id="text-org1b3892d">
<p>
The diagnosis of Lynch syndrome typically begins with a thorough medical history and physical examination, followed by genetic testing to check for specific genetic mutations associated with the disorder. If the genetic test results are positive, additional testing such as endoscopic examinations and imaging tests may be done to check for signs of cancer.
</p>
</div>
</div>
<div id="outline-container-orgcd45f2a" class="outline-3">
<h3 id="orgcd45f2a">Treatment</h3>
<div class="outline-text-3" id="text-orgcd45f2a">
<p>
Treatment for Lynch syndrome will depend on the type and stage of cancer that is present. Some common treatments include:
</p>

<ul class="org-ul">
<li>Surgery: Surgery is the most common treatment for colon and endometrial cancer associated with Lynch syndrome. The goal of surgery is to remove the cancerous tissue and any affected lymph nodes.</li>

<li>Chemotherapy: Chemotherapy uses drugs to kill cancer cells and can be used before or after surgery to shrink a tumor or kill any remaining cancer cells.</li>

<li>Radiation therapy: Radiation therapy uses high-energy X-rays to kill cancer cells and shrink tumors. It may be used in combination with surgery or chemotherapy.</li>

<li>Targeted therapy: Targeted therapy is a newer type of cancer treatment that targets specific mutations in cancer cells, making it more effective and less toxic than traditional chemotherapy.</li>

<li>Surveillance program: Close monitoring of Lynch syndrome patients with colonoscopy, endoscopy and imaging tests may be done to detect early signs of cancer and to reduce the risk of developing cancer.</li>
</ul>
</div>
</div>
<div id="outline-container-org327804f" class="outline-3">
<h3 id="org327804f">Risk assessment &amp; Prevention</h3>
<div class="outline-text-3" id="text-org327804f">
<p>
Risk assessment and prevention are important for individuals with Lynch syndrome, as well as for their family members who may also be at risk.
</p>

<ul class="org-ul">
<li>Genetic counseling: Genetic counseling is recommended for individuals with Lynch syndrome and their family members. A genetic counselor can help you understand your risk of developing cancer and can also recommend additional testing and cancer screenings.</li>

<li>Cancer screenings: Regular cancer screenings, such as colonoscopies and endometrial biopsies, are important for detecting cancer early in individuals with Lynch syndrome. The frequency and timing of these screenings will depend on the individual's specific genetic mutations and family history.</li>

<li>Lifestyle changes: Individuals with Lynch syndrome can reduce their risk of developing cancer by making lifestyle changes such as maintaining a healthy diet and weight, exercising regularly, not smoking and limiting alcohol consumption.</li>

<li>Prophylactic surgery: In some cases, prophylactic surgery may be recommended to remove the colon, uterus, or other organs at high risk of cancer development.</li>

<li>Chemoprevention: Individuals with Lynch Syndrome may take medication such as aspirin which have been shown to reduce the risk of colon cancer.</li>
</ul>
</div>
</div>
</div>
<div id="outline-container-org463be55" class="outline-2">
<h2 id="org463be55">29. Diagnosis, treatment, risk assessment and prevention of BRCA 1 and 2 associated inherited breast and ovarian cancer</h2>
<div class="outline-text-2" id="text-org463be55">
<ul class="org-ul">
<li>BRCA1 and BRCA2 are human genes that are located on chromosomes 17 and 13, respectively. They are responsible for producing tumor suppressor proteins that help repair damaged DNA and prevent the growth of cancer cells.</li>

<li>Both BRCA1 and BRCA2 genes are inherited in an autosomal dominant pattern, which means that an individual only needs to inherit one copy of the altered gene from one parent to develop an increased risk of developing breast and ovarian cancer.</li>
</ul>

<p>
<i>When these genes are functioning normally, they act as tumor suppressors and help to repair DNA damage, but when they are mutated, they can no longer perform this function, increasing the risk of developing cancer.</i>
</p>

<p>
Inheriting a mutation in either of these genes can increase a woman's risk of developing breast cancer by up to 85% and her risk of developing ovarian cancer by up to 60%.
</p>
</div>

<div id="outline-container-org14a90db" class="outline-3">
<h3 id="org14a90db">Diagnosis</h3>
<div class="outline-text-3" id="text-org14a90db">
<ul class="org-ul">
<li>Family history: A thorough family history of breast and ovarian cancer is taken and genetic counseling is recommended.</li>

<li>Genetic testing: A blood test is done to check for the presence of BRCA1 and BRCA2 mutations.</li>
</ul>
</div>
</div>
<div id="outline-container-orga1bcf7c" class="outline-3">
<h3 id="orga1bcf7c">Treatment</h3>
<div class="outline-text-3" id="text-orga1bcf7c">
<ul class="org-ul">
<li>Surgery: Prophylactic surgery, such as a mastectomy (removal of one or both breasts) and/or an oophorectomy (removal of the ovaries), can significantly reduce the risk of breast and ovarian cancer in women with a BRCA1 or BRCA2 mutation.</li>

<li>Chemotherapy: Chemotherapy may be used to shrink a tumor before surgery or to kill any remaining cancer cells after surgery.</li>

<li>Radiation therapy: Radiation therapy may be used in combination with surgery or chemotherapy.</li>

<li>Hormone therapy: Hormone therapy may be used to reduce the risk of breast cancer in women who have a BRCA1 or BRCA2 mutation and are at high risk of developing the disease.</li>
</ul>
</div>
</div>
<div id="outline-container-org58394b0" class="outline-3">
<h3 id="org58394b0">Risk assessment &amp; prevention</h3>
<div class="outline-text-3" id="text-org58394b0">
<ul class="org-ul">
<li>Genetic counseling: Genetic counseling is recommended for individuals with BRCA1 or BRCA2 mutations and their family members. A genetic counselor can help you understand your risk of developing cancer and can also recommend additional testing and cancer screenings.</li>

<li>Cancer screenings: Regular cancer screenings, such as mammograms and pelvic exams, are important for detecting cancer early in individuals with BRCA1 or BRCA2 mutations.</li>

<li>Lifestyle changes: Individuals with BRCA1 or BRCA2 mutations can reduce their risk of developing cancer by making lifestyle changes such as maintaining a healthy diet and weight, exercising regularly, not smoking, and limiting alcohol consumption.</li>
</ul>
</div>
</div>
</div>
<div id="outline-container-orge296bec" class="outline-2">
<h2 id="orge296bec">30. Genetic markers for targeted therapy in breast cancer</h2>
<div class="outline-text-2" id="text-orge296bec">
<p>
Targeted therapy is a form of cancer treatment that targets specific mutations or proteins in cancer cells, making it more effective and less toxic than traditional chemotherapy.
</p>

<p>
There are several genetic markers that have been identified as being associated with targeted therapy in breast cancer, including:
</p>

<ul class="org-ul">
<li>HER2 (human epidermal growth factor receptor 2): HER2 is a protein that helps cancer cells grow and divide. About 15-20% of breast cancers are HER2-positive, and these tumors tend to be more aggressive. Targeted therapy drugs, such as trastuzumab (Herceptin) and pertuzumab (Perjeta) can be used to target HER2-positive breast cancer.</li>

<li>ER (estrogen receptor) and PR (progesterone receptor): These receptors help to regulate the growth of breast cancer cells. About 70% of breast cancers are ER-positive and/or PR-positive, and these tumors tend to be less aggressive. Targeted therapy drugs, such as tamoxifen and fulvestrant, can be used to target ER-positive and/or PR-positive breast cancer.</li>

<li>BRCA1 and BRCA2: mutations in these genes are associated with an increased risk of developing breast and ovarian cancer. Targeted therapy drugs, such as olaparib (Lynparza) and rucaparib (Rubraca) can be used to target BRCA1 and BRCA2-associated breast cancer.</li>

<li>PIK3CA: This gene encodes for a protein that plays a role in cell growth and division. Mutations in this gene can be seen in around 20% of breast cancer cases. Targeted therapy drugs such as alpelisib (Piqray) can be used to target PIK3CA-mutated breast cancer.</li>
</ul>
</div>
</div>
<div id="outline-container-org1ad6e90" class="outline-2">
<h2 id="org1ad6e90">31. Genetic markers for targeted therapy in CRC</h2>
<div class="outline-text-2" id="text-org1ad6e90">
<p>
Colorectal cancer (CRC) is a type of cancer that affects the colon and rectum. Targeted therapy is a form of cancer treatment that targets specific mutations or proteins in cancer cells, making it more effective and less toxic than traditional chemotherapy.
</p>

<p>
There are several genetic markers that have been identified as being associated with targeted therapy in colorectal cancer, including:
</p>

<ul class="org-ul">
<li>RAS mutations: RAS genes (KRAS, NRAS, and HRAS) play a role in cell growth and division. Mutations in these genes are found in about 30% of colorectal cancer cases. Targeted therapy drugs, such as cetuximab (Erbitux) and panitumumab (Vectibix) can be used to target RAS-mutated colorectal cancer.</li>

<li>EGFR (epidermal growth factor receptor): EGFR is a protein that helps cancer cells grow and divide. Mutations in this gene are found in about 10% of colorectal cancer cases. Targeted therapy drugs, such as cetuximab and panitumumab can also be used to target EGFR-mutated colorectal cancer.</li>

<li>VEGF (vascular endothelial growth factor): VEGF is a protein that helps cancer cells create new blood vessels. Targeted therapy drugs such as bevacizumab (Avastin) can be used to target VEGF-dependent colorectal cancer.</li>

<li>Lynch Syndrome: Lynch Syndrome is an inherited disorder that increases the risk of developing certain types of cancer, particularly colorectal cancer, endometrial cancer, and other cancers of the digestive system. Targeted therapy drugs, such as olaparib (Lynparza) and rucaparib (Rubraca) can be used to target Lynch Syndrome-associated colorectal cancer.</li>
</ul>
</div>
</div>
<div id="outline-container-org967030b" class="outline-2">
<h2 id="org967030b">32. Genetic Markers for Targeted Therapy at the NSCLC</h2>
<div class="outline-text-2" id="text-org967030b">
<p>
Non-small cell lung cancer (NSCLC) is a type of lung cancer that can be treated with targeted therapy when specific genetic mutations are present. Targeted therapy is a form of cancer treatment that targets specific mutations or proteins in cancer cells, making it more effective and less toxic than traditional chemotherapy.
</p>

<p>
There are several genetic markers that have been identified as being associated with targeted therapy in non-small cell lung cancer, including:
</p>

<ul class="org-ul">
<li>EGFR mutations: EGFR (epidermal growth factor receptor) is a protein that helps cancer cells grow and divide. Mutations in the EGFR gene are found in about 10-15% of non-small cell lung cancer cases. Targeted therapy drugs such as erlotinib (Tarceva) and gefitinib (Iressa) can be used to target EGFR-mutated non-small cell lung cancer.</li>

<li>ALK mutations: ALK (anaplastic lymphoma kinase) is a protein that helps cancer cells grow and divide. Mutations in the ALK gene are found in about 5% of non-small cell lung cancer cases. Targeted therapy drugs such as crizotinib (Xalkori) and alectinib (Alecensa) can be used to target ALK-mutated non-small cell lung cancer.</li>

<li>ROS1 mutations: ROS1 is a protein that helps cancer cells grow and divide. Mutations in the ROS1 gene are found in about 1-2% of non-small cell lung cancer cases. Targeted therapy drugs such as crizotinib and entrectinib (Rozlytrek) can be used to target ROS1-mutated non-small cell lung cancer.</li>

<li>RET mutations: RET is a protein that helps cancer cells grow and divide. Mutations in the RET gene are found in about 2-3% of non-small cell lung cancer cases. Targeted therapy drugs such as selpercatinib (Retevmo) can be used to target RET-mutated non-small cell lung cancer.</li>
</ul>
</div>
</div>
<div id="outline-container-org33408a2" class="outline-2">
<h2 id="org33408a2">33. Genetic markers for targeted therapy in CML</h2>
<div class="outline-text-2" id="text-org33408a2">
<p>
Chronic myeloid leukemia (CML) is a type of blood cancer that affects the white blood cells. Targeted therapy is a form of cancer treatment that targets specific mutations or proteins in cancer cells, making it more effective and less toxic than traditional chemotherapy.
</p>

<p>
There are several genetic markers that have been identified as being associated with targeted therapy in CML, including:
</p>

<ul class="org-ul">
<li>BCR-ABL1: The Philadelphia chromosome (Ph chromosome) is a genetic alteration that results in the BCR-ABL1 gene fusion, this gene fusion is present in nearly all cases of CML. Targeted therapy drugs such as imatinib (Gleevec), nilotinib (Tasigna) and dasatinib (Sprycel) can be used to target BCR-ABL1-positive CML.</li>

<li>T315I mutation: This mutation is found in a small subset of patients with CML who develop resistance to treatment with imatinib and other tyrosine kinase inhibitors. Targeted therapy drugs such as ponatinib (Iclusig) can be used to target T315I-positive CML.</li>

<li>ABL1 mutations: These mutations can occur in patients with CML and can cause resistance to treatment with imatinib and other tyrosine kinase inhibitors. Targeted therapy drugs such as omacetaxine (Synribo) can be used to target ABL1-mutated CML.</li>
</ul>
</div>
</div>

<div id="outline-container-orge0b3816" class="outline-2">
<h2 id="orge0b3816">34. Indications and prenatal and pre-implantation diagnosis</h2>
<div class="outline-text-2" id="text-orge0b3816">
<p>
Prenatal and pre-implantation genetic diagnosis (PGD) are two different methods used to identify genetic conditions or genetic disorders before a baby is born or an embryo is implanted.
</p>

<ul class="org-ul">
<li>Prenatal diagnosis: Prenatal diagnosis is used to detect genetic conditions or chromosomal abnormalities in a developing fetus during pregnancy. It can be done through a variety of methods such as chorionic villus sampling (CVS), amniocentesis, and non-invasive prenatal testing (NIPT). Prenatal diagnosis can be offered to women who are at increased risk of having a child with a genetic condition due to their age, family history, or previous pregnancies affected by genetic disorders.</li>

<li>Pre-implantation diagnosis (PGD): PGD is a method used to identify genetic conditions in embryos before they are implanted in the uterus. It is typically used in in-vitro fertilization (IVF) procedures and involves removing one or two cells from a developing embryo and testing them for specific genetic mutations or chromosomal abnormalities. PGD can be used to screen embryos for genetic conditions that run in the family or to select embryos that are free of specific genetic conditions to prevent the transmission of these conditions to the next generation.</li>
</ul>

<p>
Indications for prenatal and pre-implantation diagnosis include:
</p>

<ul class="org-ul">
<li>A family history of a genetic disorder</li>
<li>A previous pregnancy affected by a genetic disorder</li>
<li>A known genetic disorder in one of the parents</li>
<li>Advanced maternal age</li>
<li>Positive results from a carrier screening test</li>
<li>A personal history of a genetic disorder</li>
</ul>
</div>
</div>
</div>
<div id="postamble" class="status">
<p class="author">Author: Thanos Apollo</p>
<p class="creator"><a href="https://www.gnu.org/software/emacs/">Emacs</a> 28.2 (<a href="https://orgmode.org">Org</a> mode 9.5.5)</p>
<p class="validation"><a href="https://validator.w3.org/check?uri=referer">Validate</a></p>
</div>
</body>
</html>
